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Plants have formed the foundation of traditional medicine systems throughout the world for 
thousands of years and continue to provide mankind with new remedies for various ailments.  
A large portion of the black South African population still depends on medicinal plants as 
primary health care due to its affordability, accessibility and cultural importance.  These 
medicinal plants need to be investigated since new lead compounds are often found in nature. 
Homoisoflavanones isolated from South African and Indian plants were found to exhibit anti-
inflammatory activities although the mechanism of action has not yet been determined.  A 
few reports on the antifungal activities of these compounds were also found. 
Four new and three known homoisoflavanones of the 3-benzylidene-4-chromanone type were 
synthesized and tested for anti-inflammatory and antifungal activities.  Two novel 
intermediates were also synthesised.  Enantiomers of a homoisoflavanone of the 3-benzyl-4-
chromanone types were also synthesized from the corresponding 3,5-dimethoxy phenol via 4-
chromanone in six steps.  This is the first report of the synthesis of an enantiomerically pure 
homoisoflavanone compound together with its opposite isomer.  The enantiomers and 
racemate were tested for anti-inflammatory activity. All the synthesized homoisoflavanones 
were screened for cytotoxicity.  The structures of these homoisoflavanones were elucidated 
by NMR spectroscopy along with HRMS data.  The crystal structure of a homoisoflavanone 
with anti-inflammatory and antifungal activity is reported. 
The anti-inflammatory activity of the homoisoflavanones was determined in an acute croton 
oil-induced auricular dermatitis mouse model.  The antifungal activity was performed in vitro 
against a Candida albicans strain.  Compounds were tested for cytotoxicity against a Chinese 
Hamster Ovarian (CHO) cell line using the 3-(4,5-dimethylthiazol-2-yl)-3,5-
diphenyltetrazoliumbromide (MTT) assay. 
In conclusion, the synthetic homoisoflavanones showed anti-inflammatory as well as 
antifungal activity.  Some of the compounds showed anti-inflammatory activity comparable 
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Plants have been used for medicinal purposes throughout human history, and the first 
pharmaceutical agents were derived from medicinal plants.1  Approximately three quarters of 
the world’s population and 70-80% of the African population still depend on traditional 
medicines as a primary source of healthcare.2  The African continent provides a wide 
diversity of plants useful for treatment of a variety of ailments.3  Medicinal plants of the sub-
Saharan region are readily available, relatively cheap and therefore more attractive as 
therapeutic agents than modern medicines.4, 5  South Africa hosts around 30,000 different 
plant species and medicinal plants still play an important role in the lives of most black South 
Africans.6  
The World Health Organization (WHO) recommends that proven traditional remedies should 
be incorporated within national drug policies.2  Therefore it becomes important to investigate 
the scientific rationale behind the medicinal uses of South African plants.  The destruction of 
the natural habitats of medicinal plants as well as urbanization through which traditional 
knowledge is lost increase the urgency to investigate compounds isolated from plants.7   
The potential of synthesized compounds with known modes of action is starting to decrease.  
Attention is therefore being focused on natural sources of lead compounds.8  Many drugs 
were discovered through isolation of active compounds from medicinal plants.7,8  The 
science of ethnobotany and ethnopharmacognosy are being used to established new sources 
and classes of compounds with novel modes of action.7  These are useful to provide lead 
compounds for different ailments. 
1.2 HOMOISOFLAVANONES 
1.2.1 BACKGROUND 
Böhler and Tamm isolated the first homoisoflavanones, eucomin and eucomol from Eucomis 
bicolor (Hyacinthaceae).9  Subsequently, various homoisoflavanones were also isolated from 
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other plant families.  Additional plant families from which the homoisoflavanones have been 
isolated are Agavaceae,10 Fabaceae,11 Liliaceae,12 Polygonaceae.13 A few reports of synthetic 
homoisoflavanones exist.14  Homoisoflavanone-containing plants are mostly used for pain, 
inflammation, microbial infection, digestive disorder and endocrine dysfuctions.15   
Isolated homoisoflavanones were found to exhibit a wide range of activities15 and may be 
important lead compounds for anti-inflammatory and antifungal therapies.16   
1.2.2 BASIC STRUCTURE 
Homoisoflavanones form a small class of naturally occurring oxygen heterocycles and their 
structures are similar to that of the more familiar isoflavonoids.17  Homoisoflavanones consist 
of a sixteen-carbon skeleton which include either a chromanone, chromone or chromane 
system with a benzyl or benzylidene group at position-3.18  Homoisoflavanones consists of 
four basic types, namely 3-benzylidene-4-chromanones 1, 3-benzyl-4-chromanones 2, 3-
benzyl-3-hydroxy-4-chromanones 3 and scillascillins 4.15  In this study, the 3-benzylidene-4-
chromanones 1 and 3-benzyl-4-chromanones 2 types were investigated as lead compounds.   
 
Figure 1. The four different types of homoisoflavanones 
The 3-benzylidene-4-chromanones type 1 consists of (E)- and (Z)-isomers which can undergo 
chemical interconversion.17 The homoisoflavanones 2 and 3 contains asymmetric centres at 
C-3 and, therefore consists of (R)- and (S)-enantiomers.  The absolute configuration at C-3 
was determined for a series of natural homoisoflavanones using circular dichroism and the 
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absolute (R)-configuration at C-3 was established for naturally occurring 
homoisoflavanones.19   
In the 1H-NMR spectra of 3-benzyl-4-chromanones the H-2 and H-9 protons appear as two 
ABX systems with geminal as well as vicinal coupling in the presence of H-3.  The H-2 
protons of 3-benzylidene-4-chromanones appear as one AB system in the 1H-NMR spectra 
and the alkene proton is deshielded in the aromatic region due to conjugation with the 
carbonyl group at C-4 as well as with the aromatic ring-B.17  
1.2.3 MECHANISM OF SYNTHESIS 
 
General synthetic mechanism of the homoisoflavanone. 
1.3 BIOLOGICAL ACTIVITIES OF HOMOISOFLAVANONES 
1.3.1 ANTI-INFLAMMATORY ACTIVITY 
A wide range of homoisoflavanones have been isolated from different plants around the 
world but mostly from the Hyacinthaceae family.  Only few reports on the anti-inflammatory 
activity of homoisoflavanones have been found.15   
The anti-inflammatory activity of homoisoflavanones of 3-benzylidene-4-chromanone type, 
5-8 was investigated using microsomal cell fractions as well as COX enzymes by Du Toit 
and co-workers.  Activity was measured as % inhibition of prostaglandin synthesis and of 
COX-1 and -2 enzymes at test concentrations of 250 µg/ml.20  The results revealed 
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significant inhibition of prostaglandin synthesis but weak activity against COX enzymes 
(Table 1).   
Table 1. The structure and anti-inflammatory activity of homoisoflavanones isolated from 
different plant sources.20   
% Inhibition  























70 24 NA 
Note: NA = No Activity 
Homoisoflavanones of the 3-benzyl-4-chromanone 9 and 3-benzyl-3-hydroxy-4-chromanone 
10 types were isolated from Dracaena loureiroi Gagnep. showed weak anti-inflammatory 
activity respectively against COX-1 and COX-2 enzymes at test concentrations of 10 




Figure 2. Two homoisoflavanones isolated from Dracaena loureiroi Gagnep. 
No significant COX enzyme activity was reported although good activity was reported in 
microsomal cell fractions. Therefore the mechanism of action is still unknown.20  
The anti-inflammatory effects of (E)- and (Z)-isomers 11 and 12 were established in a 
homoisoflavanone isolated from Caesalpinia pulcherrima (L.) Sw. (Fabaceae).  The nitric 
oxide (NO) production was determined by Rao et. al. using lipopolysaccharide (LPS) and 
interferon (IFN)-γ-induced systems in cultured macrophage cells.21  
 
Figure 3. Two (E)- and (Z)-homoisoflavanones isolated from Caesalpinia pulcherrima 
Compounds 11 and 12 at test concentrations of 40 µM inhibited the production of NO 
respectively with 75 and 92%.  This report gave insight into a possible mechanism of 
action.21 
1.3.2  ANTIFUNGAL ACTIVITY 
The antifungal activity of 12 isolated from Caesalpinia pulcherrima showed moderate 
antifungal activity against Aspergillus niger and Candida albicans however, it was inactive 
against Rhizopus oryzae.16   
Antifungal activity of synthetic homoisoflavanones of the 3-benzyl-4-chromanone and 3-
benzylidene-4-chromanone types were reported using the agar cup method.  Moderate 
antifungal activity was found against Aspergillus niger and Candida albicans in 3-
benzylidene-4-chromanones but not in 3-benzyl-4-chromanones.22  This method of testing is 
not always decisive because solubility differences of compounds are not taken into account. 
1.3.3  CYTOTOXICITY 
Rao and co-workers reported that compounds 11 and 12 were not toxic against macrophages 
as measured by MTT assays.22  However, four 3-benzyl-4-chromanones isolated from 
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Disporopsis aspera Engl. (Liliaceae) were reported to exhibit cytotoxic effects against six 
human cancer cell lines with IC50 values ranging from 15 to 200 uM.
12  
1.4  CONCLUSION 
Homoisoflavanones were reported to exhibit varying degrees of anti-inflammatory and 
antifungal activities.  However, only a few reports exist and it is important to expand the 
literature studies reporting these activities.  Bioactive natural compounds can be considered a 
very promising starting point for the development of new therapeutic agents with less side-
effects and new modes of action.  
1.5  AIM OF THIS STUDY 
 To synthesize novel homoisoflavanones of the 3-benzylidene-4-chromanone and 3-
benzyl-4-chromanone types.  The structures of these compounds will also be 
elucidated. 
 To screen the synthesized homoisoflavanones for anti-inflammatory and antifungal 
activity. 
 To determine the cytotoxicity of synthetic homoisoflavanones. 
1.6  RESEARCH REPORTED IN THIS THESIS 
The homoisoflavanone analogues of the 3-benzylidene-4-chromanone types were synthesized 
as well as enantiomers of a homoisoflavanone of the 3-benzyl-4-chromanone type.  1H and 
13C NMR spectroscopy along with HRMS studies supported the elucidation of structures of 
synthetic homoisoflavanones.  The homoisoflavanone analogues of the 3-benzylidene-4-
chromanone type were screened for anti-inflammatory and antifungal activity.  The 
enantiomerically pure homoisoflavanones were screened for anti-inflammatory activity.  All 
of these homoisoflavanones were screened for cytotoxicity. 
These results are presented as a series of five publications dealing with the synthesis, 
structural elucidation and biological activities of different homoisoflavanone analogues.  The 
format (numbering, experimental format etcetera) of each results chapter is different since the 
work was published (or submitted for publication) in different journals.  
In paper 1 (Chapter 2), a series of four homoisoflavanone compounds have been synthesized 
from corresponding substituted phenols via 4-chromanone in three steps.  The synthesized 
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compounds were screened for anti-inflammatory activity and cytotoxicity.  The paper was 
accepted for publication in Natural Product Research.   
In paper 2 (Chapter 3), a series of seven homoisoflavanones compounds have been 
synthesized from different substituted phenols.  These compounds were screened for 
antifungal activity and cytotoxicity.  A crystal structure of the compound exhibiting the 
highest antifungal activity was reported.  The paper was submitted to Journal of Natural 
Products. 
In paper 3 (Chapter 4), the NMR and mass spectroscopy of five synthetic homoisoflavanones 
were reported.  The paper was accepted for publication in Structural Chemistry.   
In the final paper 4 (Chapter 5), the synthesis of the pure enantiomers of a naturally occurring 
homoisoflavanone was conducted.  The synthesized enantiomers along with the racemic 
mixture were screened for anti-inflammatory activity.  The paper was submitted to Journal of 
Natural Products.   
In the final paper 5 (Chapter 6), the synthesis and crystal data of intermediate of the 
homoisoflavanone was reported.  The paper was accepted to Acta Crystallography. 
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ABSTRACT 
Aims of study: The aims of this study were to synthesize four homoisoflavanones 
(compounds 4a-d) of the 3-benzylidene-4-chromanone type, some of which were previously 
isolated from Caesalpinia pulcherrima, and to determine their anti-inflammatory activity and 
cytotoxicity.  
Materials and methods: A range of four different homoisoflavanones (compounds 4a-d) were 
synthesized from the corresponding substituted phenols. 1H and 13C-NMR data together with 
high-resolution mass spectroscopy (HRMS) data were employed to elucidate the structures. 
Anti-inflammatory activity was determined in an acute croton oil-induced auricular dermatitis 
in a mouse model. In vitro cytotoxicity was tested against a Chinese Hamster Ovarian (CHO) 
cell line using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) 
assay. 
Results: Compound 4a exhibited a tendency to inhibit oedema in a dose dependent manner 
after 3 and 6 hours treatment. Compounds 4b-d also inhibited oedema although a clear dose-
response relationship was not observed. Compounds 4a-c were found not to be cytotoxic 
whilst compound 4d showed some evidence of cytotoxicity. 
Conclusion: Compounds 4a-d exhibited anti-inflammatory activity and did not display 




Homoisoflavanones, synthesis, anti-inflammatory, cytotoxicity 
Abbreviations 
NMR, nuclear magnetic resonance; Hz, hertz; MHz, megahertz; HRMS, high resolution mass 
spectroscopy; TLC, thin-layer chromatography; DMF, N,N-dimethyl formamide; DMSO, 
dimethyl sulphoxide; NaH, sodium hydride; NaOH, sodium hydroxide; HCl, hydrochloric 
acid; CHO, chinese hamster ovarian, MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazoliumbromide; MIC, minimum inhibition concentration; mp, melting point, PPA; 
phosphoric acid. 
INTRODUCTION 
Inflammation represents a series of homeostatic events that form part of a mechanism for 
human survival against pathogens and tissue injury.  Non-steroidal anti-inflammatory drugs 
in general inhibit cyclooxygenase enzymes and are useful for the treatment of acute 
inflammation.  However, their ability to inhibit the progression of inflammation in chronic 
cases is controversial.1 These compounds also possess several unwanted side effects 
including intestinal ulceration, inhibition of platelet function and alterations in renal 
functions.1  Therefore, a need for effective and safe anti-inflammatory drugs exists and new 
lead compounds from natural sources are investigated. Plants are an established natural 
source of lead compounds.2 
Many homoisoflavanones have been isolated from different plants across the world, of which 
many are used for medicinal purposes.3, 4  These homoisoflavanone-containing plants are 
mainly used for conditions that can be ascribed to pain, inflammation, microbial infections, 
digestive disorders and endocrine dysfunctions.4  Phytochemical investigations of 
Caesalpinia pulcherrima (L.) Sw. (Fabaceae), an Indian medicinal plant have resulted in the 
isolation of homoisoflavanones of the 3-benzylidene-4-chromanone type with anti-
inflammatory activity.5 This plant has been reported to be useful in treating tridosha, fever, 
ulcers, asthma, tumors, vata and skin diseases and is also used as an abortifacient and 
emmengogue.5, 6  
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Anti-inflammatory activities of the (E)- and (Z)-isomers of 7-hydroxy-3-(4’-
methoxybenzylidene)chroman-4-one (bonducellin) previously isolated from C. pulcherrima 
were reported by Rao and co-workers.2  Both isomers inhibited LPS/IFN-γ-induced NO 
production in mouse peritoneal macrophages with IC50 values of 20 µM and 30 µM for the 
(Z)- and (E)-isomer respectively.2 Synthetic bonducellin and (E)-7-methoxy-3-(4’-
methoxybenzylidene) chroman-4-one both previously isolated from C. pulcherrima were also 
found to inhibit 5-lipoxygenase enzymes. Inhibitors of these enzymes could be useful in 
treating asthma and other inflammatory disorders.7 
In view of the anti-inflammatory properties displayed by the benzylidene-4-chromanone 
compounds isolated from C. pulcherrima, this study aims to synthesize two compounds 
previously isolated from this plant including (E)-7-methoxy-3-(4’-methoxybenzylidene) 
chroman-4-one together with two structurally similar compounds of which one is novel.7  
Furthermore the anti-inflammatory activity in an acute croton oil-induced auricular dermatitis 
mouse model as well as the cytotoxicity of these compounds were determined. 
MATERIALS AND METHODS 
Chemistry 
A range of four different homoisoflavanones were synthesized from the corresponding 
substituted phenols. The synthesis of homoisoflavanones and their derivatives from 
commercially available reagents was carried out using the general synthetic approach shown 
in Scheme 1.  
The reaction of the substituted phenols (1a-c) with 3-bromopropanoic acid using sodium 
hydroxide as base furnished substituted 3-phenyloxypropanoic acids (2a-c).8  The propanoic 
acids were cyclised using polyphosphoric acid to give the substituted chroman-4-ones (3a-
c).9  Base catalyzed condensation of substituted chroman-4-one with different substituted 
benzaldehydes afforded the homoisoflavanones (4a-d).  The method was adapted from 
literature.7-11  The homoisoflavanone (4d) is novel and the other three homoisoflavanones 
(4a-c) were previously reported.  The 1H NMR data for homoisoflavanone (4a), (4b) and (4c)   







Scheme 1.  Reagents and conditions for the chemical synthesis of substituted 
homoisoflavanones. 
EXPERIMENTAL 
All reaction mixtures were magnetically stirred and monitored by TLC using Kieselgel 60 
F254 from Merck (Darmstadt, Germany).  1H and 13C-NMR spectra were recorded on a 
Bruker AVANCE III at 400 MHz with CDCl3 as internal reference.  The value for the 
chemical shift (δ) is given in ppm and coupling contants (J) are reported in Hertz (Hz).  
Melting points were recorded with a Mel-Temp melting point apparatus in open capillaries 
and are uncorrected.  The high-resolution mass spectroscopy (HRMS) data was recorded on a 
Waters Micromass Q-Tof Micro mass spectrometer with a lock spray source.   
Preparation of substituted 3-phenoxypropanoic acid derivatives (2a-c) 
To a DMF solution (10 ml), NaH (32.46 mmol) was added at a temperature of 10–15 °C.  
Each substituted phenol (32.46 mmol) in DMF (15 ml) was added to the reaction mixture and 
stirred at room temperature for 1 hour.  A solution of 3-bromopropionic acid (38.96 mmol) in 
DMF (15 ml) was then added dropwise at 0 °C and the reaction mixture was stirred for 12 
hours at room temperature.  It was then diluted with methanol (20 ml) and acidified with 10% 
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HCl.  The product was extracted with ethyl acetate (3× 50 ml). The combined ethyl acetate 
layer was washed with water (1×50 ml), brine (1×50 ml) and then dried over magnesium 
sulphate. The residue obtained after evaporation of the solvent was chromatographed over a 
silica gel column, using a mixture of ethyl acetate/hexane (30:70) as eluent to obtain the title 
products 2a-c (yield, 35-40%). 
3-(2,3-dimethoxyphenoxy) propanoic acid (2a) 
1H NMR (400 MHz, CDCl3) δ: 2.88 (t, J=6.3 Hz, 2H, H-2), 3.81 (s, 3H, Ar-OMe-2’), 3.84 (s, 
3H, Ar- OMe-3’), 4.29 (t, J=6.3 Hz, 2H, H-1), 6.59 (d, J=8.4 Hz, 2H, H-4’ & H-6’), 6.96 (dd, 
J=8.3, 8.3 Hz, 1H, H-5’); 13C NMR (100 MHz, CDCl3) δ: 34.4 (C-2), 56.1 (OMe-3’), 60.8 
(OMe-2’), 64.4 (C-1), 105.9 (C-4’), 107.2 (C-6’), 123.6 (C-5’), 138.7 (C-2’), 152.2 (C-1’), 
153.6 (C-3’), 176.8 (C-3); Mass m/z = 227 [M+1]+;  Rf = 0.23 on silicagel with ethyl 
acetate:hexane (30:70). 
3-(3-methoxyphenoxy) propanoic acid (2b) 
1H NMR (400 MHz, CDCl3) δ: 2.84 (t, J=6.3 Hz, 2H, H-2), 3.78 (s, 3H, Ar- OMe-3’), 4.23 
(t, J=6.2 Hz, 2H, H-1), 6.46-6.53 (m, 3H, H-2’, H-4’, H-6’), 7.17 (t, 1H, H-5’); 13C NMR 
(100 MHz, CDCl3) δ: 34.3 (C-2), 55.2 (OMe-3’), 63.0 (C-1), 101.1 (C-2’), 106.6 (C-4’), 
106.8 (C-6’), 129.9 (C-5’), 159.6 (C-1’), 160.8 (C-3’), 177.1 (C-3); Mass m/z = 197 [M+1]+; 
Rf = 0.25 on silicagel with ethyl acetate:hexane (30:70). 
3-(3,5-dimethoxyphenoxy) propanoic acid (2c)  
1H NMR (400 MHz, CDCl3) δ: 2.83 (t, J=6.2 Hz, 2H, H-2), 3.76 (s, 6H, Ar- OMe-3’,5’), 4.20 
(t, J=6.2 Hz, 2H, H-1), 6.09 (s, 3H, H-2’, H-4’, H-6’); 13C NMR (100 MHz, CDCl3) δ: 34.2 
(C-2), 55.3 (OMe-3’,5’) 63.0 (C-1), 93.4 (C-4’), 93.5 (C-2’,6’), 160.2 (C-1’), 161.5 (OMe-
3’,5’), 176.8 (C-3); Mass m/z = 227 [M+1]+; Rf = 0.24 on silicagel with ethyl acetate:hexane 
(30:70). 
Preparation of substituted chroman-4-ones (3a-c)  
A mixture of substituted 3-phenoxypropanoic acid (10 mmol) and polyphosphoric acid (10 g) 
was stirred whilst being heated to 85-90 °C for 2 h.  The red coloured syrup thus obtained 
was poured into crushed ice and extracted with diethyl ether (2×50 ml).  The extract was 
washed with 3M NaOH (30 ml), water (50 ml) and dried over magnesium sulphate.  The 
residue obtained after evaporation of the solvent was chromatographed through a silica gel 
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column using an appropriate mixture of ethyl acetate/hexane as eluent to obtain the title 
product (3a-c) (yield, 50-55%). 
7,8-dimethoxychroman-4-one (3a)  
1H NMR (400 MHz, CDCl3) δ: 2.74 (t, J=6.3 Hz, 2H, H-3), 3.83 (s, 3H, Ar-OMe-7), 3.88 (s, 
3H, Ar- OMe-8), 4.54 (t, J=6.4 Hz, 2H, H-2), 6.60 (d, J=8.9, 1H, H-6), 7.64 (d, J=8.9 Hz, 
1H, H-5); 13C NMR (100 MHz, CDCl3) δ: 37.5 (C-3), 56.1 (OMe-7), 61.0 (OMe-8), 67.6 (C-
2), 105.5 (C-6), 116.5 (C-4a), 123.1 (C-5), 136.7 (C-8), 155.7 (C-8a), 158.5 (C-7), 190.7 (C-
4); Mass m/z = 209 [M+1]+;  Rf = 0.55 on silicagel with ethyl acetate:hexane (30:70).   
7-methoxychroman-4-one (3b)  
1H NMR (400 MHz, CDCl3) δ: 2.74 (t, J=6.4 Hz, 2H, H-3), 3.83 (s, 3H, Ar- OMe-7), 4.51 (t, 
J=6.4 Hz, 2H, H-2), 6.40 (d, J=2.4 Hz, 1H, H-8), 6.57 (dd, J=2.4, 8.9 Hz, 1H, H-6), 7.82 (d, 
J=8.8 Hz, 1H, H-5); 13C NMR (100 MHz, CDCl3) δ: 37.4 (C-3), 55.6 (OMe-7), 67.3 (C-2), 
100.7 (C-8), 109.8 (C-6), 115.2 (C-4a), 128.8 (C-5), 163.7 (C-8a), 165.9 (C-7), 190.5 (C-4); 
Mass m/z = 179 [M+1]+; Rf = 0.57 on silicagel with ethyl acetate:hexane (30:70). 
5,7-dimethoxychroman-4-one (3c) 
1H NMR (400 MHz, CDCl3) δ: 2.71 (t, J=6.4 Hz, 2H, H-3), 3.81 (s, 3H, Ar- OMe-7), 3.87 (s, 
3H, Ar- OMe-5), 4.43 (t, J=6.4 Hz, 2H, H-2), 6.04 (s, 2H, H-6 & H-8); 13C NMR (100 MHz, 
CDCl3) δ: 38.7 (C-3), 55.5 (OMe-7), 56.0 (OMe-5), 66.7 (C-2), 92.8 (C-8), 93.3 (C-6), 106.3 
(C-4a), 162.2 (C-5), 165.2 (C-8a), 165.7 (C-7), 189.1 (C-4); Mass m/z = 209 [M+1]+; Rf = 
0.54 on silicagel with ethyl acetate:hexane (30:70).    
Preparation of substituted homoisoflavanones 
A mixture of substituted chroman-4-one (2.4 mmol), substituted benzaldehyde (3.6 mmol) 
and piperidine (7-10 drops) was heated at 80 °C for 2-48 h.  The reaction was monitored by 
TLC, using 3:7 ethyl acetate/hexane as solvent system.  The reaction mixture was cooled, 
diluted with water (15 ml), acidified with 10% HCl and then extracted with ethyl acetate 
(3×30 ml).  The combined ethyl acetate layer was washed with water (30 ml), brine (30 ml) 
and dried over magnesium sulphate.  The residue obtained after evaporation of the solvent 
was chromatographed with a silica gel column using an appropriate mixture of ethyl 





Yield 58 %; mp 172-175 ºC; yellow powder; 1H NMR (400 MHz, CDCl3) δ: 3.87 (s, 3H, Ar-
OMe-7), 3.94 (s, 3H, Ar-OMe-8), 5.41 (d, J=1.52 Hz, 2H, H-2), 5.90 (broad s, 1H, OH), 6.70 
(d, J=8.8 Hz, 1H, H-6), 6.93 (d, J=8.8 Hz, 2H, H-3’,5’), 7.22 (d, J=8.5 Hz, 2H, H-2’,6’), 7.80 
(s, 1H, H-9), 7.81 (d, J=8.8 Hz, 1H, H-5); 13C NMR (100 MHz, CDCl3) δ: 54.3 (OMe-7), 
59.3 (OMe-8), 66.3 (C-2), 104.2 (C-6), 114.0 (C-4a), 115.3 (C-3’,5’), 122.2 (C-5), 125.2 (C-
1’), 126.8 (C-2’,6’), 130.3 (C-3), 134.8 (C-9), 135.4 (C-8), 153.0 (C-8a), 155.2 (C-4), 156.7 
(C-7), 179.7 (C-4); HRMS calculated for C18H17O5 [M + H]+ 313.0998, found 313.1071; Rf = 
0.51 on silicagel with ethyl acetate:hexane (30:70).   
(E)-7-methoxy-3-(4-methoxybenzylidene)-4-chromanone (4b) 
Yield 70 %; mp 126-128 ºC; pale yellow needles; 1H NMR (400 MHz, CDCl3) δ: 3.83 (s, 3H, 
Ar-OMe-7), 3.85 (s, 3H, Ar-OMe-4’), 5.35 (d, J=1.8 Hz, 2H, H-2), 6.39 (d, J=2.4 Hz, 1H, H-
8), 6.62 (dd, J=2.4, 8.8 Hz, 1H, H-6), 6.95 (d, J=8.8 Hz, 2H, H-3’,5’), 7.25 (d, J=8.8 Hz, 2H, 
H-2’,6’), 7.80 (s, 1H, H-9), 7.95 (d, J=8.8 Hz, 1H, H-5); 13C NMR (100 MHz, CDCl3) δ: 55.3 
(C-4’-OMe), 55.6 (C-7-OMe), 68.0 (C-2), 100.7 (C-8), 110.3 (C-6), 114.2 (C-4a), 115.8 (C-
3’,5’), 127.1 (C-1’), 128.8 (C-5), 129.6 (C-2’,6’), 131.9 (C-3), 136.5 (C-9), 160.5 (C-4’), 
162.9 (C-8a), 165.8 (C-7), 180.9 (C-4); HRMS calculated for C18H17O4 [M + H]+ 297.1049, 
found 297.1121; Rf = 0.62 on silicagel with ethyl acetate:hexane (30:70). 
(E)-5,7-dimethoxy-(3-benzylidene)-4-chromanone (4c) 
Yield 76 %; mp 100-103 ºC; dark yellow powder; 1H NMR (400 MHz, CDCl3) δ: 3.82 (s, 
3H, Ar-OMe-5), 3.91 (s, 3H, Ar-OMe-7), 5.20 (d, J=1.7 Hz, 2H, H-2), 6.12 ( d, J=2.2 Hz, 
1H, H-6), 6.06 (d, J=2.2 Hz, 1H H-8), 7.27 (d, J=8.0 Hz, 2H, H-2’,6’), 7.27-7.37 (m, 3H, H-
3’, H-4’, H-5’), 7.82 (s, 1H, H-9); 13C NMR (100 MHz, CDCl3) δ: 55.1 (OMe-7), 55.6 (OMe-
5), 67.4 (C-2), 93.6 (C-6,8), 107.2 (C-4a), 128.6 (C-4’), 129.9 (C-2’,6’), 131.9 (C-3), 134.8 
(C-1’), 135.8 (C-9), 162.0 (C-8a), 164.7 (C-5), 165.8 (C-7), 179.5 (C-4); HRMS calculated 
for C18H17O4 [M + H]+ 297.1049, found 297.1121; Rf = 0.58 on silicagel with ethyl 
acetate:hexane (30:70).     
Novel (E)-5,7-dimethoxy-3-(4-hydroxybenzylidene)-4-chromanone (4d)  
Yield 68 %; mp 197-200 ºC; yellow powder; 1H NMR (400 MHz, CDCl3) δ: 3.76 (s, 3H, Ar-
OMe-7), 3.82 (s, 3H, Ar-OMe-5), 5.17 (d, J=1.4 Hz, 2H, H-2), 6.00 (d, J=2.2 Hz, 1H, H-6), 
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6.05 (d, J=2.2 Hz, 1H, H-8), 7.11 (d, J=8.5 Hz, 2H,  H-2’,6’), 6.85 (d, J=8.5 Hz, 2H, H-
3’,5’),  7.70 (s, 1H, H-9); 13C NMR (100 MHz, CDCl3) δ: 54.5 (OMe-7), 55.0 (OMe-5), 66.5 
(C-2), 92.5 (C-6), 92.5 (C-8), 106.1 (C-4a), 114.7 (C-3’,5’), 126.0 (C-1’), 128.0 (C-3), 130.9 
(C-2’,6’), 135.0 (C-9), 155.9 (C-4’), 163.6 (C-8a), 164.5 (C-5), 164.7 (C-7), 178.8 (C-4); 
HRMS calculated for C18H17O5 [M + H]+ 313.0998, found 313.1071; Rf = 0.50 on silicagel 
with ethyl acetate:hexane (30:70). 
Assessment of croton oil-induced oedema 
The synthesized homoisoflavanones were assessed for their potential anti-inflammatory 
activity.  Ethical approval (003/09/Animal) from the University of KwaZulu-Natal Animal 
Ethics subcommittee was obtained prior to the investigation of acute croton oil-induced 
auricular dermatitis in a mouse model.  Guidelines by the University of KwaZulu-Natal 
Animal Ethics Subcommittee and Biomedical Resources Unit for the maintenance and 
treatment of laboratory animals were followed. 
Eight-week old male Balb/c mice of approximately 30 g each were used.  Equal volumes of 
croton oil (25 µl) were mixed with acetone (25 µl) as vehicle and applied (50 µl total volume; 
1 hour) onto the inner surface of the right auricle of each mouse to induce oedema.13  Acetone 
has not been documented to have an anti-inflammatory effect by itself.14  Thereafter, the 
homoisoflavanones were dissolved in acetone and applied (0.05, 0.1 and 0.5 mg in 50 µl; 3 or 
6 hours treatment) onto the right auricle to assess the reduction in oedema.  The non-steroidal 
anti-inflammatory drug diclofenac (0.05 mg; 6 hours treatment) was included as a positive 
control. 
Mice were euthanized after treatment for 3 and 6 hours.  From each mouse, left and right 
auricle biopsy specimens were obtained with a 6 mm biopsy punch and then weighed. 
Cytotoxicity assay 
In vitro cytotoxicity of the synthesized homoisoflavanones was tested against a Chinese 
Hamster Ovarian (CHO) cell line using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) assay. 
The MTT assay is a colorimetric assay to determine cellular growth and survival, and 
compares well with other available assays.15, 16  The tetrazolium salt MTT was used to 
measure cell viability. 
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The homoisoflavanones were prepared in a 2 mg/ml stock solution containing 10% v/v 
DMSO.  Emetine was used as the reference drug at an initial concentration of 100 µg/ml 
serially diluted in 10-fold to obtain 6 concentrations, the lowest being 0.001 µg/ml.  
Homoisoflavanones were diluted similarly.  The DMSO solvent system had no measurable 
effect on cell viability (data not shown). 
Data analysis 
Data are reported as the mean ± standard error of the mean of 3 (cytotoxicity assays) and at 
least 4 (anti-inflammatory assays) independent experiments with triplicate and duplicate 
measurements respectively.  For the anti-inflammatory assays, oedema was quantified by 
calculating the difference in weights of the right and left auricular biopsy specimens.  The 
value is expressed as a percentage of the croton oil control.  For the cytotoxicity assays, the 
50% inhibitory concentration (IC50) values were obtained from full dose-response curves 
using a non-linear dose-response curve fitting analysis.  GraphPad Prism version 5 
(GraphPad Software, San Diego, CA, USA) was used to analyse and present the data.  
Statistical comparisons were made by one-way ANOVA followed by Bonferroni’s post-test 
for multiple comparisons, or by Student’s two-tailed paired t test to determine P values.  A 
value of P < 0.05 was considered significant. 
RESULTS AND DISCUSSION 
Reduction of croton oil-induced oedema 
Four homoisoflavanones with different substitution patterns were synthesized and tested for 
anti-inflammatory activities.  The ability of the homoisoflavanones to inhibit acute croton oil-




Figure 1.  The anti-inflammatory activity of synthetic homoisoflavanones.   
Compounds 4a-d (represented by A-D) were tested in a mouse model of acute croton oil-
induced auricular contact dermatitis.  Oedema was measured after treatment with 0.05, 0.1 
and 0.5 mg homoisoflavanone in acetone for 3 and 6 hours.  Treatment with 0.05 mg 
diclofenac was included as a positive control (indicated as “Diclo”).  Data are the mean ± 
standard error of the mean of duplicate measurements from 4 independent experiments.  
Statistical comparisons of activity were by one-way ANOVA followed by Bonferroni’s post-
test for multiple comparisons; *, P < 0.05; ***, P < 0.001 versus croton oil only control; †, P 
< 0.05 versus 6 hours treatment. 
Compound 4a exhibited a tendency to inhibit oedema in a dose dependent manner after 3 and 
6 hours treatment.  Activity increased with increasing doses and optimal activity was 
observed at 0.5 mg.  After 6 hours treatment, activity decreased for all doses and was 
significant for 0.1 mg (3 h: 46.4 ± 5.1%; 6 h: 29.0 ± 5.0%).  Compounds 4b-d also inhibited 
oedema although a clear dose-response relationship was not observed.  For compounds 4b-d, 
optimal activity was observed with 0.5 mg, 0.1 mg and 0.05 mg respectively after 3 hours 
treatment.  After 6 hours treatment, the activity of compounds 4b and 4d respectively was 
significantly decreased at 0.5 mg (3 h: 54.2 ± 5.6%; 6 h: 22.2 ± 4.4%) and 0.05 mg (3 h: 49.2 
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± 8.3%; 6 h: 39.4 ± 3.8%).  However, compound 4c did not exhibit a significant decrease in 
activity after 6 hours at the doses tested. 
Compound 4a and 4d have similar substitution patterns. The presence of the methoxy group 
at C-8 (4a) or at C-5 (4d) in ring A apparently has an insignificant influence on the biological 
activity of these compounds.  Compounds 4c and 4d have the same substitution pattern in 
ring A, but 4c lacks the hydroxyl group at C-4’of ring B.  This compound exhibited a 
tendency of higher activity that was maintained after 6 hours.  Overall, the compound with an 
unsubstituted B ring (4c) seemed to show higher activity than compounds with substituted B 
rings (4a, 4b, 4d).   
Cytotoxicity 
Cytotoxicity is an important factor to consider when testing for any biological activity.  A 
relatively high value may reduce the therapeutic potential of the compounds tested.  The in 
vitro cytotoxicity of compounds 4a-d was investigated and the IC50 values are represented in 
Table 1. Compounds 4a-c were found not to be cytotoxic whilst compound 4d showed some 
evidence of cytotoxicity. 
CONCLUSION 
In conclusion we were able to synthesize four structurally similar homoisoflavanones. 
Structures were assigned based on NMR and Mass spectrometric data. These compounds 
were tested for the first time in an animal model and all of them were found to be active. It 
appeared as if the substitution pattern in ring A did not have a significant effect on the 
activity but an unsubstituted B ring increased activity. Compounds 4a-c were not cytotoxic.  
Only compound 4d showed some degree of cytotoxicity but this was 40 times lower than the 








Table 1.  The in vitro cytotoxicity of synthetic homoisoflavanones against Chinese Hamster 
Ovarian (CHO) cells using the MTT assay. 
Compound IC50 (µg/ml) 
4a 67.1 ± 16.2 
4b >100 
4c 45.3 ± 8.7 
4d 2.6 ± 0.5 
emetine 0.06 ± ND 
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ABSTRACT 
A series of seven homoisoflavanone analogues 4a-g were synthesized from the corresponding 
substituted phenols via 4-chromanone in three steps.  The structures were elucidated with 1H 
and 13C-NMR together with High-Resolution Mass Spectroscopy (HRMS) data.  The X-ray 
crystal structure of compound 4c (E)-5,7-dimethoxy-3-benzylidene-4-chromanone, is 
reported.  Analogues were evaluated for their antifungal activity against Candida albicans 
and compound 4c showed the highest activity.  The cytotoxicity of the compounds were 
investigated against Chinese Hamster Ovarian (CHO) cells in a MTT assay. 
Keywords 
Homoisoflavanones, synthesis, anti-fungal, cytotoxicity, crystal structure. 
Abbreviations 
CHO, Chinese Hamster Ovarian; DMF, N,N-dimethyl formamide; DMSO, dimethyl 
sulphoxide; HCl, hydrochloric acid; HRMS, high resolution mass spectroscopy; Hz, hertz; 
IC50, inhibition concentration 50 %; MHz, megahertz; MIC, minimum inhibition 
concentration; mp, melting point; MTT, 3-(4,5-dimethylthiazol-2-yl)-3,5-diphenyl 
tetrazoliumbromide; NaH, sodium hydride; NaOH, sodium hydroxide; NMR, nuclear 




There has been a growing concern regarding the increase in severe opportunistic fungal 
infections that threaten public health.1  This is associated with the wide-spread use of broad-
spectrum antibiotics as well as immunosuppressive, anticancer, and antiretroviral drugs.2-4  
Candida albicans is present in the gut of about 80% of the human population and a major 
opportunistic pathogen.5  The high incidence of acquired immune deficiency syndrome 
(AIDS) in sub-Saharan Africa allowed this fungus to become a source of major health 
problems in these developing countries.6 
The successful treatment of fungal infections has remained problematic due to the emergence 
of wide-spread resistance against current antifungal drugs.  The deficiency of health care 
clinics adequately equipped to treat patients in Southern Africa further contribute towards the 
problem.  Many of these patients revert to traditional healers who use medicinal plants to 
treat Candida infections.6  Medicinal plants are good sources of potential antifungal drugs. 
Homoisoflavanone-containing plants have been used medicinally to treat fungal and other 
skin infections.7-10  Homoisoflavanones have also been reported to possess antifungal 
activity.11-13  These compounds are structurally related to isoflavonoids, but consist of a 
sixteen-carbon atom skeleton as opposed to the fifteen-carbon atom skeleton of isoflovanoids.  
Four types of homoisoflavanones can be distinguished, namely 3-benzyl-4-chromanones, 3-
benzylidene-4-chromanones, 3-benzyl-3-hydroxy-4-chromanones and scillascilins.14  The 3-
benzylidene-4-chromanone type was reported to exhibit antifungal activity.11-13 
In this study, we report (1) the synthesis of 3-benzylidene-4-chromanone analogues with 
varying substitution patterns, (2) the antifungal activities and cytotoxicity of the analogues, 
and (4) the crystal structure of the most active antifungal compound, 4c.  The chemical 
structure of compounds 4c, 4d and 4f-g were not previously reported, and the antifungal 
activities of all the synthesized compounds are unknown. 
Chemistry 
The synthesis of homoisoflavanones and its derivatives from commercially available reagents 
was carried out using the general synthetic approach shown in Scheme 1.  The reaction of 
substituted phenols 1a-c with 3-bromopropanoic acid using sodium hydride as base furnished 
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substituted 3-phenyloxypropanoic acids 2a-c,15 which were cyclised using polyphosphoric 
acid to give substituted chroman-4-ones 3a-c.16  Base catalyzed condensation of the 
substituted chroman-4-ones with a series of substituted benzaldehydes afforded 
homoisoflavanones 4a-g. The method was adapted from literature.17-19 
 
 
Reagents and conditions: (i) 3-Bromopropionic acid, NaH, DMF, rt, 12h, 35-40 %;  
(ii) PPA, 80 °C, 4h, 50-55 %; (iii) substituted benzaldehyde, piperidine, 70-80 °C, 2-48 h, 52-
86 % 
Scheme 1.  Chemical synthesis of substituted homoisoflavanones. 
The X-ray crystal structure of compound 4c was determined at low temperature from a 





Table 1.  Crystallographic Parameters and Refinement Statistics for Compound 4c. 
Crystal data  
Chemical formula C18H16O4 
Mr 296.31 
Crystal system, space group Monoclinic, P21/c 
Temperature (K) 173 
a, b, c (Å) 14.8454 (10), 5.4119 (4), 17.3821 (12) 
b (°) 93.738 (1) 
V (Å3) 1393.54 (17) 
Z 4 
Radiation type Mo Ka 
m (mm-1) 0.10 
Crystal size (mm) 0.19 × 0.14 × 0.08 
Data collection 
Diffractometer Bruker Kappa Duo Apex II Diffractometer 
Absorption correction Multi-scan SADABS (Sheldrick, 1997) 
Tmin, Tmax 0.666, 0.746 
No. of measured, independent and 
observed [I > 2s(I)] reflections 
14158, 3464, 2833   
Rint 0.040 
Refinement 
R[F2 > 2s(F2)], wR(F2), S 0.040,  0.109,  1.04 
No. of reflections 3464 
No. of parameters 199 
No. of restraints 0 
H-atom treatment H-atom parameters constrained 





Figure 1.  (a) X-ray crystal structure of compound 4c showing the molecular conformation 
and numbering scheme.  All non-hydrogen atoms are indicated as thermal ellipsoids with a 
probability level of 50%.  Hydrogen atoms are rendered as capped cylinders. (b) Space-filling 
plot (van der Waals radii) of the X-ray structure of 4c highlighting the intramolecular H···H 
steric interaction that leads to the nonplanar conformation of the molecule. 
The structure of 4c exhibits a conspicuously nonplanar conformation characteristic of all 5,7-
dimethoxy-3-(benzylidene)-4-chromanone derivatives (Figure 1).  The C3–C2–C10–C11 and 
C2–C10–C11–12 torsion angles measure 173.1(1)o and 19.3(2)o, respectively. The dihedral 
angle between the 4-chromanone ring and the phenyl ring containing C11 (Ring B in Scheme 
1) is 31.6(3)o, consistent with a substantial out-of-plane tilt of this substituent ring.  The 4-
chromanone ring is essentially planar as whole, but with localized nonplanarity confined to 
the region encompassing the ethereal oxygen of Ring C (Scheme 1, Figure 1).  The deviations 
of the ether oxygen atom O1 and methylene carbon atom C1 from the mean plane of the 4-
chromanone ring system measure 0.24(1) Å and 0.33(1) Å, respectively. One important 
conformation-defining intramolecular short contact exists for 4c, specifically the 
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hydrogen⋅⋅⋅hydrogen interaction H12⋅⋅⋅H1B (2.034(2) Å).  This is shown in the van der Waals 
plot of Figure 1b and is considerably shorter than the sum of the van der Waals radii of two 
hydrogen atoms (2.4 Å). Analysis of the unit cell packing of 4c indicates that there are 
symmetric (aromatic)C–H⋅⋅⋅O type hydrogen bonds between neighbouring molecules in the 
solid state (Figure 2) such that 4c crystallizes as an inversion pair or dimer with 
crystallographically-imposed inversion symmetry. One short H⋅⋅⋅O contact (shorter than the 
limit  ∑(van der Waals radii) – 0.2 Å) exists between the carbonyl oxygen O2 and a 
neighbouring methoxy group’s hydrogen atom (H18C⋅⋅⋅O2, 2.49(1) Å). This interaction is 
inconsequential to the molecular conformation of 4c. 
 
Figure 2. Ball and cylinder model of the hydrogen-bonded dimer involving symmetric 
(aromatic)C–H⋅⋅⋅O interactions between neighbouring molecules of 4c. The dimer has 
crystallographic inversion symmetry (centre of inversion, i, indicated). 
RESULTS AND DISCUSSION 
In this study, seven homoisoflavanones were synthesized of which four are novel.  The 
antifungal activities were unknown. 
Chemistry 
Five of the synthesized homoisoflavanones have identical substitution patterns in ring A 4d-
g.  Ring B contains either no substituent or substituents varying in hydrophobicity, electronic 
properties or size.  The influence of substituents on ring A was investigated by adding two 




X-ray structure of 4c 
The X-ray structures of eleven homoisoflavanones have been reported in the literature20; the 
present structure of 4c is, however, novel.  Inspection of the available crystallographic data 
suggests that the 4-chromanone ring is conformationally flexible in all of these compounds 
with the 2,3-dihydro-4H-pyran4-one moiety capable of adopting half-chair conformations in 
which the methylene carbon (C2, Scheme 1) is either displaced above or below the mean 
plane of the bicyclic 4-chromanone ring system. Thus, for example, the parent compound, 
(3E)-5,7-dimethoxy-3-(benzylidene)-4-chromanone, crystallizes in the triclinic space group 
P-1 with the unit cell containing the inversion-related pair of conformers with the methylene 
carbon above and below the mean plane of the 4-chromanone ring system.21  The present 
compound crystallizes in the space group P21/c and, because of the inversion centre shown in 
Figure 2, both conformers of the 2,3-dihydro-4H-pyran-4-one moiety are simultaneously 
present in the solid state. 
As noted above, the salient feature of the molecular structure of 4c is its nonplanar 
conformation, this despite a conjugated p-electron system involving Ring A, the carbonyl 
group of Ring C, and the benzylidene substituent.  The key determinant of the nonplanar 
conformational architecture is the van der Waals repulsion that occurs between the hydrogen 
atoms of the methylene group of Ring C and the benzylidine ortho-H atom (6' position in 
Scheme 1).  This is readily seen in the space-filling plot of Figure 1b; the H1B···H12 contact 
distance is 0.37-Å shorter than the sum of the van der Waals radii of the two hydrogen atoms, 
consistent with a considerable degree of steric strain brought about by the electronic 
requirement of a planar conjugated p-electron system and the steric clash engendered by the 
juxtaposition of the ortho-H atom of the benzylidine group and the methylene hydrogen 
atoms.  The solution to these opposing intramolecular forces is evidently to have partial 
rotation about the benzylidene double bond (i.e., an out-of-plane tilt of 7° for the C3–C2–
C10–C11 torsion angle) and a canted phenyl group orientation (ca. 32°) relative to the mean 
plane of the 4-chromanone ring system.  The latter distortion is naturally achieved by a ca. 
19° rotation about the C10–C11 bond in the molecule (Figure 1).  Finally, it is worth noting 
that the overall conformational architecture observed for 4c matches the conformations of 
other substituted 4-chromanones (torsion angles within 13o)22; the methoxy groups of 4c do 
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not, as might be expected, have any significant impact on the overall conformation of rings 
A–C of the compound. 
Assessment of antifungal activity 
The susceptibility of Candida albicans to compounds 4a-g was determined and depicted in 
Figure 3.  The MIC50 values depicted in Table 2 represents the potency of the synthesized 
compounds, whilst the Emax values are indicative of their efficacies.  A relatively low potency 
suggests that higher concentrations are needed to achieve 50% activity.  Efficacy is indicative 
of the maximum response obtainable.  The MIC50 and Emax values are summarised in Table 2. 
 
Figure 3.  Fungal susceptibility to synthetic homoisoflavanones.  Growth of Candida 
albicans was measured against increasing concentrations (0, 30, 50, 70, 100, 150, 200, 250 
and 300 µM) of compounds 4a-g.  Data are the mean ± standard error of the mean of 
duplicate measurements from four independent experiments.  For each compound, growth 
was significantly inhibited (P < 0.05 or less) at each concentration tested. 
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Table 2.  The MIC50 and Emax values of compounds 4a-g against Candida albicans. 
Compound MIC50 (µM) Emax (% inhibition) 
(4a) 200 55.9 ± 2.0 
(4b) 42 80.1 ± 2.0 
(4c) 25 87.3 ± 1.8 
(4d) >300 31.8 ± 2.2 
(4e) 150 73.7 ± 2.7 
(4f) 70 62.3 ± 3.5 
(4g) 160 60.4 ± 4.5 
Compound 4c exhibited the highest potency and efficacy.  The B ring of this compound was 
unsubstituted.  Compounds 4d-g were substituted respectively with hydroxy, methoxy, 
chloride and fluoride in the 4’ position.  Of these compounds, 4e exhibited the highest 
efficacy followed by 4f-g which exhibited slightly lower efficacies.  Compound 4d exhibited 
the lowest efficacy.  These results suggest that the size and hydrophobicity of the substituents 
may play a role in the activity.  Compounds 4a and 4d both contain a 4’-hydroxy group in 
ring B but respectively 7,8-dimethoxy or 5,7-dimethoxy substituents in ring A.  Results 
suggest that the 7,8-dimethoxy substitution pattern leads to reduced activity.   The activity of 
compound 4e was increased by removing the 5-methoxy group in ring A, resulting in 
compound 4b with a monosubstituted ring A.  It is suggested that the substituents in the B 
ring increases the activity in the following order: hydroxy < halogens < methoxy < 
unsubstitued. 
These results are encouraging and provide novel lead compounds in the search for antifungal 
drugs with favourable toxicity profiles.  
Cytotoxicity 
The in vitro cytotoxicity of compounds 4a-g was investigated and the IC50 values are 
represented in Table 3. 
Assessment of cytotoxicity in mammalian cells is important in the development of new drugs 
to ensure selectivity between species.  Even if the cytotoxicity profile of a compound is not 
favourable, it does not prohibit its future development.  Many fungal infections are 
superficial and topical application of drugs may reduce systemic toxicity.  Compounds 4d, 4f 
and 4g were the most cytotoxic compounds with IC50 values below 5 µg/ml.  Compounds 4a 
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and 4e showed slight cytotoxicity and compound 4b was not cytotoxic at the concentrations 
tested.  Considering activity and cytotoxicity profiles, it is suggested that compounds 4b and 
4e are most favorable, although compound 4c exhibited the highest antifungal potential.  
Compound 4c was significantly more potent than all the other compounds tested, suggesting 
that a relatively lower dose may be needed to reach optimum activity. 
Table 3.  The in vitro cytotoxicity of synthetic homoisoflavanones against Chinese Hamster 
Ovarian (CHO) cells using the MTT assay. 
Compound IC50 (µg/ml) 
4a 67.1 ± 16.2 
4b >100 ± ND 
4c 2.6 ± 0.5 
4d 45.3 ± 8.7 
4e 59.4 ± 18.9 
4f 4.9 ± 1.9 
4g 3.8 ± 0.3 




1H and 13C-NMR spectra were recorded at ambient temperature at 400 and 100 MHz, 
respectively, using a Bruker AVANCE III spectrophotometer.  All the spectra were acquired 
in CDCl3 with chemical shifts reported as δ values in part per million (ppm) and were 
calibrated according to the internal CDCl3 (7.24 ppm) solvent residual peak.  The data are 
reported as follows: multiplicity (br, broad; s, singlet; d, doublet; t, triplet; dd, double 
doublet; m, multiplet), coupling constants (J) are reported in Hertz (Hz). Melting points were 
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recorded with a Melt-Temp melting point apparatus in open capillaries and are uncorrected.  
The high-resolution mass spectroscopy (HRMS) was recorded on a Waters Micromass Q-
Tof-II Micro mass spectrometer with a lock spray source. 
Preparation of substituted 3-phenoxypropanoic acid 2a-c 
To a DMF solution (10 ml), NaH (32.46 mmol) was added at a temperature of 10–15°C.  
Each substituted phenol (32.46 mmol) in DMF (15 ml) was added to the reaction mixture and 
stirred at room temperature for 1 hour.  A solution of 3-bromopropionic acid (38.96 mmol) in 
DMF (15 ml) was then added dropwise at 0°C and the reaction mixture was stirred for 12 
hours at room temperature.  It was then diluted with methanol (20 ml) and acidified with 10% 
HCl.  The product was extracted with ethyl acetate (3× 50 ml). The combined ethyl acetate 
layer was washed with water (1×50 ml), brine (1×50 ml) and then dried over magnesium 
sulphate. The residue obtained after evaporation of the solvent was chromatographed over a 
silica gel column, using a mixture of ethyl acetate/hexane (30:70) as eluent to obtain the title 
products 2a-c (yield, 35-40%). 
3-(2,3-dimethoxyphenoxy) propanoic acid 2a 
1H NMR (400 MHz, CDCl3) δ: 2.88 (t, J=6.3 Hz, 2H, H-2), 3.81 (s, 3H, Ar-OMe-2’), 3.84 (s, 
3H, Ar-OMe-3’), 4.29 (t, J=6.3 Hz, 2H, H-1), 6.59 (d, J=8.4 Hz, 2H, H-4’ & H-6’), 6.96 (dd, 
J=8.3, 8.3 Hz, 1H, H-5’); 13C NMR (100 MHz, CDCl3) δ: 34.4, 56.1, 60.8, 64.4, 105.9, 
107.2, 123.6, 138.7, 152.2, 153.6, 176.8; MS (ESI): m/z 227 [M+1]+. 
3-(3-methoxyphenoxy) propanoic acid 2b 
1H NMR (400 MHz, CDCl3) δ: 2.84 (t, J=6.3 Hz, 2H, H-2), 3.78 (s, 3H, Ar-OMe-3’), 4.23 (t, 
J=6.2 Hz, 2H, H-1), 6.46-6.53 (m, 3H, H-2’, H-4’, H-6’), 7.17 (t, 1H, H-5’); 13C NMR (100 
MHz, CDCl3) δ: 34.3, 55.2, 63.0, 101.1, 106.6, 106.8, 129.9, 159.6, 160.8, 177.1; MS (ESI): 
m/z 197 [M+1]+.   
3-(3,5-dimethoxyphenoxy) propanoic acid 2c 
1H NMR (400 MHz, CDCl3) δ: 2.83 (t, J=6.2 Hz, 2H, H-2), 3.76 (s, 6H, Ar-OMe-3’,5’), 4.20 
(t, J=6.2 Hz, 2H, H-1), 6.09 (s, 3H, H-2’, H-4’, H-6’); 13C NMR (100 MHz, CDCl3) δ: 34.2, 




Preparation of substituted 4-chromanones 3a-c 
A mixture of substituted 3-phenoxypropanoic acid (10 mmol) and polyphosphoric acid (10 g) 
was stirred whilst being heated to 85-90°C for 2 h.  The red coloured syrup thus obtained was 
poured into crushed ice and extracted with diethyl ether (2×50 ml).  The extract was washed 
with 3N NaOH (30 ml), water (50 ml) and dried over magnesium sulphate.  The residue 
obtained after evaporation of the solvent was chromatographed through a silica gel column 
using an appropriate mixture of ethyl acetate-hexane as eluent to obtain the title product 3a-c 
(yield, 50-55%). 
7,8-dimethoxy-4-chromanone 3a 
1H NMR (400 MHz, CDCl3) δ: 2.74 (t, J=6.3 Hz, 2H, H-3), 3.83 (s, 3H, Ar-OMe-7), 3.88 (s, 
3H, Ar- OMe-8), 4.54 (t, J=6.4 Hz, 2H, H-2), 6.60 (d, J=8.9, 1H, H-6), 7.64 (d, J=8.9 Hz, 
1H, H-5); 13C NMR (100 MHz, CDCl3) δ: 37.5, 56.1, 61.0, 67.6, 105.5, 116.5, 123.1, 136.7, 
155.7, 158.5, 190.7; Mass m/z = 209 [M+1]+;  Rf = 0.55 on silicagel with ethyl 
acetate:hexane (30:70).   
7-methoxy-4-chromanone 3b 
1H NMR data were in agreement with those previously reported23; MS (ESI): m/z 179 
[M+1]+. 
5,7-dimethoxy-4-chromanone 3c 
1H NMR (400 MHz, CDCl3) δ: 2.71 (t, J=6.4 Hz, 2H, H-3), 3.81 (s, 3H, Ar- OMe-7), 3.87 (s, 
3H, Ar- OMe-5), 4.43 (t, J=6.4 Hz, 2H, H-2), 6.04 (s, 2H, H-6 & H-8); 13C NMR (100 MHz, 
CDCl3) δ: 38.7, 55.5, 56.0, 66.7, 92.8, 93.3, 106.3, 162.2, 165.2, 165.7, 189.1; Mass m/z = 
209 [M+1]+; Rf = 0.54 on silicagel with ethyl acetate:hexane (30:70).  
Preparation of substituted homoisoflavanones 
A mixture of substituted chroman-4-one (2.4 mmol), substituted benzaldehyde (3.6 mmol) 
and piperidine (7-10 drops) was heated at 80°C for 2-48 h.  The reaction was monitored by 
TLC, using 4:6 ethyl acetate/hexane as solvent system.  The reaction mixture was cooled, 
diluted with water (15 ml), acidified with 10% HCl and then extracted with ethyl acetate 
(3×30 ml).  The combined ethyl acetate layer was washed with water (30 ml), brine (30 ml) 
and dried over magnesium sulphate.  The residue obtained after evaporation of the solvent 
34 
 
was chromatographed with a silica gel column using an appropriate mixture of ethyl acetate-
hexane as eluent to obtain homoisoflavanones (yield, 52-86%). 
(E)-7,8-dimethoxy-3-(4-hydroxybenzylidene)-4-chromanone 4a 
Yield 58%; mp 172-175°C; yellow powder; 1H NMR (400 MHz, CDCl3) δ: 3.87 (s, 3H, Ar-
OMe-7), 3.94 (s, 3H, Ar-OMe-8), 5.41 (d, J=1.52 Hz, 2H, H-2), 5.90 (broad s, 1H, OH), 6.70 
(d, J=8.8 Hz, 1H, H-6), 6.93 (d, J=8.8 Hz, 2H, H-3’,5’), 7.22 (d, J=8.5 Hz, 2H, H-2’,6’), 7.80 
(s, 1H, H-9), 7.81 (d, J=8.8 Hz, 1H, H-5); 13C NMR (100 MHz, CDCl3) δ: 54.3, 59.3, 66.3, 
104.2, 114.0, 115.3, 122.2, 125.2, 126.8, 130.3, 134.8, 135.4, 153.0, 155.2, 156.7, 179.7; 
HRMS calculated for C18H17O5 [M + H]+ 313.0998, found 313.1071.  
(E)-7-methoxy-3-(4-methoxybenzylidene)-4-chromanone 4b 
Yield 70%; mp 126-128°C; pale yellow needles; 1H NMR data were in agreement with those 
previously reported19; HRMS calcd for C18H17O4 [M+1]+ 297.1049, found 297.1121. 
(E)-5,7-dimethoxy-3-(4-benzylidene)-4-chromanone 4c 
Yield 76%; mp 100-103°C; dark yellow powder; 1H NMR (400 MHz, CDCl3) δ: 3.82 (s, 3H, 
Ar-OMe-7), 3.91 (s, 3H, Ar-OMe-5), 5.2 (d, J=1.7 Hz, 2H, H-2), 6.06 ( d, J=2.2 Hz, 1H, H-
6), 6.12 (d, J=2.2 Hz, 1H, H-8), 7.27 (d, J=8.0 Hz, 2H, H-2’,6’), 7.27-7.37 (m, 3H, H-3’, H-
4’, H-5’), 7.82 (s, 1H, H-9); 13C NMR (100 MHz, CDCl3) δ: 55.1, 55.6, 67.4, 93.6, 107.2, 
128.6, 128.9, 129.9, 131.9, 134.8, 135.8, 162.8, 164.7, 165.8, 179.5; HRMS calculated for 
C18H17O4 [M + H]+ 297.1049, found 297.1121. 
Novel (E)-5,7-dimethoxy-3(4-hydroxybenzylidene)-4-chromanone 4d 
Yield 68%; mp 197-200°C; yellow powder; 1H NMR (400 MHz, CDCl3) δ: 3.76 (s, 3H, Ar-
OMe-7), 3.82 (s, 3H, Ar-OMe-5), 5.17 (d,  J=1.4 Hz, 2H, H-2), 6.00 (d, J=2.2 Hz, 1H, H-8), 
6.05 (d, J=2.2 Hz, 1H, H-6),  6.85 (d, J=8.5 Hz, 2H H-3’,5’),  7.11 (d, J=8.5 Hz, 2H,  H-
2’,6’), 7.70 (s, 1H, H-9); 13C NMR (100 MHz, CDCl3) δ: 54.5, 55.0, 66.5, 92.5, 106.1, 114.7, 
126.0, 128.0, 130.9, 135.0, 155.9, 163.6, 164.7, 164.7, 178.8; HRMS calcd for C18H17O5 







Yield 71%; mp 171-174°C; pale yellow powder; 1H NMR data were in agreement with those 
previously reported23; HRMS calcd for C19H19O5 [M+1]+ 327.1154, found 327.1227 
Novel (E)-5,7-dimethoxy-3-(4-chlorobenzylidene)-4-chromanone 4f 
Yield 86%; mp 126-129°C; pale yellow powder; 1H NMR (400 MHz, CDCl3) δ: 3.74 (s, 3H, 
Ar-OMe-7), 3.82 (s, 3H, Ar-OMe-5), 5.08 (d, J=1.8 Hz, 2H, H-2), 5.97 (d, J=2.2 Hz, 1H, H-
8), 6.03 (d, J=2.2 Hz, 1H, H-6), 7.11 (d, J=8.4 Hz, 2H, H-2’, 6’), 7.30 (d, J=2.2 Hz, 2H, H-3’, 
5’), 7.65 (s, 1H, H-9); 13C NMR (100 MHz, CDCl3) δ: 54.5, 55.1, 66.2, 92.5, 92.6, 106.2, 
127.0, 129.4, 131.0, 131.5, 133.5, 133.9, 161.2, 163.5, 164.8, 178.0; HRMS calcd for 
C18H16ClO4 [M+1]+ 331.0659, found 331.0732. 
Novel (E)-5,7-dimethoxy -3-(4-fluorobenzylidene)-4-chromanone 4g 
Yield 63%; mp 102-105°C; pale yellow needles; 1H NMR (400 MHz, CDCl3) δ: 3.83 (s, 3H, 
OMe-7), 3.92 (s, 3H, OMe-5),  5.19 (d, J=1.6 Hz, 2H, H-2), 6.07 (d, J=2.3 Hz, 1H, H-8), 
6.13 (d, J=2.3 Hz, 1H, H-6), 7.12 (t, 2H, H-3’,5’), 7.25-7.28 (m, 2H, H-2’, 6’), 7.77 (s, 1H, 
H-9); 13C NMR (100 MHz, CDCl3) δ: 55.6, 56.2, 67.3, 93.6, 93.6, 107.1, 115.8, 130.9, 131.6, 
134.6, 137.7, 161.6, 162.8, 164.6,  165.8, 179.3; HRMS calcd for C18H16FO4 [M+1]+ 
315.0954, found 315.1027. 
Crystallography 
Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-Kα radiation (χ = 0.71073 Å). Data 
collection was carried out at 173(2) K to minimise thermal motion effects. Temperature was 
controlled by an Oxford Cryostream cooling system (Oxford Cryostat). Cell refinement and 
data reduction were performed using the program SAINT.24 The data were scaled and 
empirical absorption corrections were performed using SADABS.25 The structure was solved 
by direct methods using SHELXS-9725 and refined by full-matrix least-squares methods 
based on F2 using SHELXL-9725 and using the graphic interface program X-Seed.26, 27 The 





Assessment of fungal susceptibility 
Sabouraud dextrose broth was inoculated with Candida albicans and grown in an incubator 
(37°C; optical density of 0.5 at 600 nm).  C. albicans (ATCC strain 10231) culture was 
obtained from American Type Culture Collection (Manassas, VA, USA).  The broth was 
prepared according to the manufacturer’s protocol.  The fungal susceptibility assay was based 
on a microplate method but with modifications.  Compounds 4a-g were prepared in pure 
DMSO at stock concentrations of 1.5, 2.5, 3.5, 5, 7.5, 10, 12.5 and 15 mM.  Firstly, 100 
µl/well of sterile broth was added into a clear, sterile 96-well microtitre plate (Corning Life 
Sciences, Acton, MA, USA).  Secondly, 6 µl/well of the compound at the appropriate 
concentration above was added and the plate tapped to mix the contents.  Thirdly, 94 µl/well 
of sterile water was added and the plate tapped.  Finally, 100 µl/well of the culture was added 
and the plate tapped and incubated (37°C; 18 hours).  Therefore, with a final volume/well of 
300 µl and a dilution factor of 50×, the final concentration of DMSO/well was 2% v/v and 
the final concentrations of each compound/well were 30, 50, 70, 100, 150, 200, 250 and 300 
µM.  Fungal growth was not significantly inhibited by the 2% v/v DMSO (data not shown).  
The positive control was amphotericin B (100 µM final concentration) against C. albicans 
(inhibition of growth 98.9 ± 0.7%).  Fungal growth was quantified by optical density (600 
nm) in a microplate reader (BioTek ELx800, Winooski, VT, USA). 
Cytotoxicity assay 
In vitro cytotoxicity of the synthesised homoisoflavanones was tested against a Chinese 
Hamster Ovarian (CHO) cell line using the 3-(4,5-dimethylthiazol-2-yl)-3,5-
diphenyltetrazoliumbromide (MTT) assay. 
The MTT assay is a colourimetric assay to determine cellular growth and survival, and 
compares well with other available assays.28, 29  The tetrazolium salt MTT was used to 
measure cell viability. 
The homoisoflavanones were prepared in a 2 mg/ml stock solution containing 10% v/v 
DMSO.  Emetine was used as the reference drug at an initial concentration of 100 µg/ml 
serially diluted in 10-fold to obtain 6 concentrations, the lowest being 0.001 µg/ml.  
Homoisoflavanones were diluted similarly.  The DMSO solvent system had no measurable 





Data are reported as the mean ± standard error of the mean of four independent experiments 
with duplicate measurements.  Fungal growth was quantified as a percentage of the control 
without the test compound.  GraphPad Prism (version 5.02; GraphPad Software, San Diego, 
CA, USA) was used to present and analyze the data.  MIC50 values were deduced from the 
graphs.  Statistical comparisons between 0 and each concentration for each compound were 
made by one-way ANOVA followed by Bonferroni’s post-test to determine P values.  A 
value of P < 0.05 was considered significant. 
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ABSTRACT 
A series of five homoisoflavanone analogues have been synthesized from the corresponding 
3,5-methoxy phenols via 4-chromanone in three steps.  The complete NMR elucidation of 
these homoisoflavanone analogues is reported.  The use of 2D NMR techniques (COSY, 
NOESY, HSQC and HMBC) proved to be very useful tools in the elucidation of 
homoisoflavanone analogues.  The homoisoflavanone analogues exhibit an AA’BB’ spin 
pattern in the ring B of the homoisoflavanone.  These homoisoflavanone analogues are 
potential antifungal and anti-inflammatory agents. 
Keywords  
Homoisoflavanone, Synthesis, Anti-inflammatory, Antifungal, 2D NMR.   
INTRODUCTION 
Homoisoflavanones belong to a small homogeneous group of naturally occurring oxygen 
heterocycles.1  The basic homoisoflavanone structure consists of a 16-carbon skeleton, which 
includes a chromane system with a benzyl or benzylidine group at position 3.2  Natural 
homoisoflavanone (3-benzylidine-4-chromanones) such as Bonducellin, Isobonducellin, 2’-
Methoxybonducellin and Sappanone A have been isolated from different plants.3-8  Few 
reports on the biological activity of homoisoflavanones have been found.  However according 
to previous studies, natural homoisoflavanones exhibit anti-inflammatory, antibacterial, anti-




The synthesis of homoisoflavanones (3-benzylidine-4-chromanones) is well established17 and 
although a variety of homoisoflavanones have been isolated from many different plants, it 
appears that more is known about the biosynthesis and chemistry of these compounds than 
about their biological activities and its relation to their structures.  Previously, a NMR study 
of a similar type was reported on natural homoisoflavanones.18-20  In this study, we report the 
synthesis of 3-benzylidene-4-chromanone analogues with varying substitution patterns at the 
4’-position of the B-ring.  The lead compound (3,5-dimethoxy-3-benzyl-4-chromanone 7a, 
chapter-5), a type of homoisoflavanone, was isolated from the Southern African 
Hyacinthaceae family and screened for anti-inflammatory activity.9  Based on the lead 
compound we synthesized compound 4d and its analogues with different substitution patterns 
at the 4’-position of the B-ring  The products showed good anti-inflammatory17 and anti-
fungal activity.21  The structures of compounds 4c22 and 4e23, 24 have been previously 
reported, respectively.  
RESULTS AND DISCUSSION 
This study describes the synthesis and structural elucidation of homoisoflavanones 4c-g.  The 
synthesis of homoisoflavanone analogues from commercially available reagents was carried 
out using the general synthetic approach shown in Scheme 1.  The reaction of 3,5 dimethoxy 
phenol with 3-bromopropanoic acid using sodium hydride as base furnished 3-(3,5-
dimethoxy phenoxy)propanoic acid,25 which was cyclised using polyphosphoric acid to give 
7,8 dimethoxy chroman-4-one.26  Base catalyzed condensation of 7,8-dimethoxy-4-
chromanone with different substituted benzaldehyde results in the synthesis of 




Note: * = not studied 2D NMR spectroscopy 
Scheme 1: General synthesis of homoisoflavanone analogues 4c-g. 
Infrared spectroscopy (IR) is regularly used to confirm the functional groups of organic 
compounds and was therefore applied to our modified compounds 4c-g.  The structure of 
compound 4c, with no substitution at C-4’ in the ring-B, is a good starting point for the 
elucidation.  The basic IR peaks for compound 4c resulted in a sharp single peak at 2940 cm-1 
for the C-H stretching mode in the aromatic rings A and B.  The peak at 1664 cm-1  and 1567 
cm-1 indicated the presence of a carbonyl group (C=O, C-4) with symmetric and asymmetric 
conjugation with the double bond (C=C, C-3 and C-9).  The peaks at 1465 cm-1 and 1421 cm-
1 represents the symmetrical stretching of alkene (C=C) group of aromatic ring and 1339 cm-1 
and 1317 cm-1 indicated asymmetrical stretching of the aromatic ring.  Furthermore the peak 
at 1107 cm-1 indicated the C-O-C (C-8a and C-2) ether stretching in compound 4c, 
confirming the most prominent functional groups in this molecule.  In compound 4d, the 
hydroxy-group (OH) at C-4’ in ring-B causes a broad single peak at 3377 cm-1.  As expected, 
no significant differences in the IR spectra for the remaining compounds were observed. 
Nuclear magnetic resonance (NMR) spectroscopy has become an essential tool for studying 
the structure of a broad variety of systems, and was here applied to elucidate the structures of 
the substituted compounds 4c to 4g.  All 1D 1H and 13C chemical shifts and couplings of the 
homoisoflavanone analogues are reported in Table 1.  The only methylene protons (H-2) and 
the well-separated H-9 alkene proton are two convenient points of entry for the elucidation of 
compound 4c.  The 1D NMR spectrum of compound 4c shows two methylene protons, which 
exhibit a geminal coupling constant (2JHH) of 1.7 Hz.  The well separated alkene proton H-9 
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appears as a singlet and is deshielded in the aromatic region due to conjugation with the 
carbonyl group at C-4, as well as with the aromatic ring-B.  The 1H-NMR spectrum showed 
two meta-coupled protons doublet, which is therefore assigned to H-6 and H-8 in the 
aromatic ring B, respectively, indicative of a 5,7 disubstituted aromatic ring.  Furthermore the 
1H-NMR spectrum shows a doublet for two protons (by integration), which were coupled 
with 3 adjacent protons, registering as overlaying multiplets.  These remaining protons were 
assigned to H-2’ and H-6’ of the aromatic ring B.  
 
Figure 1: Long range interactions of homoisoflavanone found by NMR measurements. 
The COSY and NOESY spectra enabled us to confirm the prior assignment.  The COSY 
spectrum shows a correlation between H-2 and the methine bridge proton H-9.  COSY 
correlations are most intense for vicinal H-C-C-H protons (3JHH), the COSY correlation 
between H-2 and H-9 is transfered via an additional carbon atom and is therefore accounted 
as long-range couplings (4JHH).  These are only observed for specific conformations.
27  We 
also observed a NOESY correlation between H-2 and H-2’/H-6’ (overlapping) and between 
H-2 and H-9, though with less intensity, indicating that ring B is positioned as the E-isomer 
(the cis-isomer).  The NOESY spectrum shows correlation of H-6 with the protons of the 
methoxy group OC(H-5)3 and H-8 with the methoxy group OC(H-7)3.  These observations 
further indicated a disubstituted methoxy group at position C-5 and C-7 in ring A.  
Confirmation of the assignments for OC(H-5)3 and OC(H-7)3 is possible by comparing the 
chemical shifts of the methyl protons.  Since OC(H-5)3 is close to the carbonyl oxygen at C-
4, it should experience a through space deshielding effect (H-bonding between the OC(H-5)3 
methyl protons and the carbonyl oxygen group at C-4 can also contribute to the deshielding 
effect), moving the OC(H-5)3 protons at higher δ value.  The COSY spectrum also shows 
correlation between the protons H-2’/H-6’ and H-3’/H-5’ and a complex correlation between 
H-3’/H-5’ and H-4’.  
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After the unambiguous assignment of the existing protons, the corresponding carbon atoms 
were identified using the HSQC and HMBC spectra.  In the HMBC spectrum a correlation of 
H-2, our preferred starting point, with a carbonyl carbon was observed.  The latter was 
therefore assigned to C-4 in ring C.  Correlations of H-2 to a quaternary alkene carbon led to 
identification of C-3 and the alkene bridge carbon C-9.  These assignments were also 
confirmed from the HSQC data, indicating that compound 4c is a homoisoflavanone of the 3-
benzylidene-4-chromanone type.  In addition, the HMBC spectrum shows correlations of H-6 
with a quaternary carbon C-4a, a tertiary carbon C-8, the latter confirmed by HSQC, and two 
quaternary carbons bound to oxygens which were assigned to C-5 and C-7, respectively.  It 
was possible to distinguish between the C-5 and C-7 methoxy groups, because the HMBC 
spectrum shows correlation of H-8 with carbon atom C-7, the carbon of the methoxy group 
attached to C-7, and to a quaternary carbon, assigned to C-8a.  The H-6 proton shows 
correlations to carbon atom C-5, C-7, C-4a and methoxy carbon at C-5 but not to methoxy 
group at C-7.  The HMBC spectrum also allowed for the assignment of the carbon atoms in 
ring B by first correlating H-9 to the quaternary carbon C-1’ and the two equivalent tertiary 
carbons C-2’/C-6’.  HSQC correlations of these carbons with H-2’/H-6’ confirm these 
assignments.  H-3’/H-5’ show HMBC correlations with the previously assigned C-2’/C-6’ 
carbon atoms and also with three aromatic/tertiary carbons, assigned to the chemical 
equivalent C-3’/C-5’ and to C-4’.  It was possible to distinguish between C-3’/C-5’ and C-4’ 
by utilizing the HMBC spectrum.  The details of proton and carbon chemical shifts values for 
compound 4c are reported in table 1. 
 






Table 1: 1H and 13C chemical shift (δ) and JHH-couplings dataa of compound 4c.  
Atom δ 1Hb in ppm J(Hz) δ 13Cb in ppm 
2 5.21 1.7 67.4 
3 -- -- 131.9 
4 -- -- 179.5 
4a -- -- 107.2 
5 -- -- 164.7 
6 6.12 2.2 93.6 
7 -- -- 165.8 
8 6.06 2.2 93.6 
8a -- -- 162.8 
1’ -- -- 134.8 
2’/6’ 7.27 8.0 129.9 
3’/5’ 7.27-7.34 -- 128.6 
4’ 7.27-7.34 -- 128.9 
9 7.82 -- 135.8 
OC(H-5)3 3.91 -- 56.1 
OC(H-7)3 3.82 -- 55.6 
a 9.4T Bruker Avance III (400 MHz 1H and 100 MHz 13C)  
b Referring to the solvent CDCl3. 
The 1H and 13C NMR spectra of compounds 4d-g were also completely assigned based on the 
same methodology described for compound 4c.  The change in NMR data of these 











Table-2: 1H chemical shift differences (Δδ) in ppm dataa between compound 4d to 4g 
relative to compound 4c. 
Atom 
Compound 4d 
(Δδ 1Hb) ppm 
Compound 4e 
(Δδ 1Hb) ppm 
Compound 4f 
(Δδ 1Hb) ppm 
Compound 4g 
(Δδ 1Hb) ppm 
2 nc 0.02 0.05 0.04 
3 -- -- -- -- 
4 -- -- -- -- 
4a -- -- -- -- 
5 -- -- -- -- 
6 nc nc nc nc 
7 -- -- -- -- 
8 nc nc nc nc 
8a -- -- -- -- 
1’ -- -- -- -- 
2’/6’ 0.16 0.03 0.16 nc 
3’/5’ 0.45 0.36 0.19 0.12 
4’ -- -- -- -- 
9 0.06 0.05 nc 0.18 
OC(H-5)3 nc nc nc nc 
OC(H-7)3 0.03 nc 0.17 nc 
a 9.4T Bruker Avance III (400 MHz 1H and 100 MHz 13C)  
b Referring to the solvent CDCl3. 
 ‘nc’ = no change was detectable. 
Comparing the chemical shifts of the molecules due to substitution at position C-4’, no or 
only insignificantly small changes where observed for the 1H and 13C resonances on ring A 
and B, with the exception of the bridge atoms C-9 and its surroundings, such as C-2 and C-3 
(see Table 2 and 3).  The strongest changes in general, as expected are found in the change of 
chemical shift for atom C-4’, followed by C-3’/C-5’, C1’ and C-2’/C-6’, with exception of 
compound 4f, where carbon chemical shift changes of C-1’ and C-2’/C-6’ are larger than for 
C-3’/C-5’.  
One can hypothesize that in the ring-B of compound 3, the electron pair of the hydroxyl 
group substitution at C-4’ generates an electron donating effect in the aromatic ring with the 
result of a larger shielding effect for C-3’/C-5’ than for C-2’/C-6’.  Similarly the methoxy-
group of compound 4f at C-4’ causes an electron donating effect in the aromatic ring which 
46 
 
results in a larger shielding effect for C-3’/C-5’ than for C-2’/C-6’.  In compound 4f, the 
protons of C-3’/C-5’ experience a larger de-shielding effect than H-2’/H-6’ due to two 
opposing effects exerted by the (C-4’)-Cl group: an electron donation effect due to 
conjugation and an electron withdrawal effect due to induction.  However chlorine is a large 
atom and has a smaller electronegative effect therefore, for compound 4g, the substitution of 
fluorine at the C-4’ position of the aromatic ring-B influences the chemical shift in the 
opposite way than that of compound 4f most possibly due to the smaller fluorine atom with a 
stronger electron withdrawing inductive effect on ring-B.  In compound 4g, the protons H-
2’/H-6’ couple with protons H-3’/H-5’ as well as with the fluorine atom.  One therefore 
expects to observe a multiplet but the splitting pattern merged into a triplet (J=5,8.6 Hz).28  
The splitting pattern for protons H-3’/H-5’ clearly shows a multiplet.  Interestingly, the 
protons on the methoxy-group at C7 [OC(H-7)3] in compound 4f shows slight shielding (Δδ 
1H of 0.17 ppm) compared to compound 4c.  Furthermore, the bridge proton H9 of 
compounds 4d-g shows significant shielding in comparison to compound 4c, ranging from 
Δδ 1H = 0.05 to 0.09 ppm.  The 13C chemical shift values for compound 4f and 4g differs due 

























2 nc nc 1.2 nc 
3 3.1 1.8 nc nc 
4 nc nc 1.5 nc 
4a 1.1 nc 1.2 nc 
5 nc 2.0 2.9 1.9 
6 nc nc nc nc 
7 1.1 nc 1.0 nc 
8 1.3 nc nc nc 
8a nc 1.7 nc 1.8 
1’ 8.6 7.4 2.6 3.8 
2’/6’ 2.0 -1.7 2.2 -1.7 
3’/5’ 13.9 14.5 -1.3 13.0 
4’ 27.0 31.4 5.0 32.7 
9 nc nc 2.5 1.2 
OC(H-5)3 1.1 nc 1.1 nc 
OC(H-7)3 1.1 nc 1.1 nc 
a 9.4T Bruker Avance III (400 MHz 1H and 100 MHz 13C) 
b referring to the solvent CDCl3. 
‘nc’ = no change was detectable 
EXPERIMENTAL 
All reagents and solvents were purchased from Aldrich, Merck and Fluka.  TLC used 
Kieselgel 60 F254 from Merck (Darmstadt, Germany).  All NMR spectra were recorded on a 
9.4T Bruker AVANCE III 400 MHz instrument at room (298K) temperature with CDCl3 as 
an internal standard using a sample concentration in the range of 10 (mg/µl).  The 
spectrometer was equipped with a BBO probe with 400 MHz S1 and with a z gradient.  The 
data was recorded and analyzed with Topspin 2.1 (Bruker, Karlsruhe, Germany).  Standard 
Bruker pulse sequences were used: 1D 1H (32 scans) and 13C with 1H decoupling and 1024 
scans, 1H and 13C hard pulse width for all experiments was 10 µs at -3 db and 8.4 µs at -2 db, 
respectively.  1H and 13C spectral width was 20.54 and 238 ppm, respectively and therefore 
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acquisition time was 1.9923 and 1.38s.  Relaxation delays were set to 1,5 and 2 s for 1H and 
13C, respectively and carrier frequency was set to 4 ppm for 1H or 100 ppm for 13C.   
2D 1H-13C HSQC and HMBC were acquired with the same parameters, 256 and 128 complex 
t1 points were recorded, respectively.  The number of scans was adapted to the sample 
concentration to assure a proper signal to noise ratio.  The HSQC experiment was recorded 
using Echo/Antiecho-TPPI gradient selection with decoupling during acquisition and using 
trim pulses for transfer of magnetization.  The HMBC experiment was optimized for long-
range couplings and uses gradient pulses to select zero and double quantum coherence.  2D 
1H-1H NOESY and COSY experiments were recorded with 256 and 128 complex t1 points 
respectively.  For 1H-1H NOESY experiment the mixing time was recorded with 300 ms.  For 
the COSY experiment gradient pulses were used for coherence selection.  The values for 
chemical shift (δ) is given in ppm and coupling contants (J) in Hertz (Hz), presented in table 
1-3 for compounds 4c-g.   
Melting points were recorded with a Mel-Temp melting point apparatus in open capillaries 
and are uncorrected.  The high-resolution mass spectroscopy (HRMS) were recorded on a 
Waters Micromass Q-Tof Micro mass spectrometer with a lock spray source.  The mass 
spectroscopy (MS) were recorded ona Waters Acquity Ultra Performance LC with ZQ 
detector in ESI mode. 
General procedure for the synthesis of substituted homoisoflavanones 
A mixture of substituted chroman-4-one (2.4 mmol, 500 mg), substituted benzaldehyde (3.6 
mmol) and piperidine (7-10 drops) was heated at 80OC for 2 h - 36 h (reaction was monitored 
by TLC – detail follow for each compound).  The reaction mixture was cooled, diluted with 
water (15 ml) and acidified with 10 % HCl. The ethyl acetate layer was extracted (3 × 30 ml), 
the combined ethyl acetate layers were washed with water (30 ml), brine (30 ml) and dried 
over magnesium sulphate.  The residue obtained after evaporation of the solvent was 
chromatographed using a silica gel column with a mixture of ethyl acetate-hexane (20:80) as 
eluent to give homoisoflavanones 4c-g (63-79 %) yield.  The NMR data for all compounds 
are included in Tables 1 – 3. 
(E)-5,7-dimethoxy-3-benzylidene-4-chromanone (4c) 
Yield 76 %; mp 100-103 ºC; dark yellow powder (Rf = 0.61 in 30 % ethyl acetate in hexane).  
IR: 2940 cm-1, 1664 cm-1, 1602 cm-1, 1466 cm-1, 1421 cm-1, 1250 cm-1, 1209 cm-1, 1109 cm-1, 
49 
 
940 cm-1, 755 cm-1.  HRMS calculated for C18H17O4 (M + H+) 297.1049, found 297.1131. 
(E)-5,7-dimethoxy-3-(4-hydroxybenzylidene)-4-chromanone (4d) 
Yield 68 %; mp 197-200 ºC; yellow powder (Rf = 0.43 in 30 % ethyl acetate in hexane).  
IR 3176 cm-1, 2923 cm-1, 1644 cm-1, 1601 cm-1, 1570 cm-1, 1452 cm-1, 1420 cm-1, 1265 cm-1, 
1210 cm-1, 1157 cm-1, 969 cm-1, 809 cm-1. HRMS calculated for C18H17O5 (M + H+) 
313.0998, found 313.1070. 
(E)-5,7-dimethoxy-3-(4-methoxybenzylidene)-4-chromanone (4e) 
Yield 71 %; mp 171-174 ºC; pale yellow powder (Rf = 0.58 in 30 % ethyl acetate in hexane).  
IR: 2935 cm-1, 1664 cm-1, 1602 cm-1, 1456 cm-1, 1421 cm-1, 1247 cm-1, 1208 cm-1, 1109 cm-1, 
945 cm-1, 798 cm-1. HRMS calculated for C19H19O5 (M + H+) 327.1154, found 327.1225.  
(E)- 5,7-dimethoxy-3-(4-chlorobenzylidene)-4-chromanone (4f) 
Yield 79 %; mp 126-129 ºC; pale yellow powder (Rf = 0.54 in 30 % ethyl acetate in hexane).  
IR: 2938 cm-1, 1664 cm-1, 1602 cm-1, 1456 cm-1, 1249 cm-1, 1208 cm-1, 1109 cm-1, 798 cm-1. 
HRMS calculated for C18H16ClO4 (M + H+) 331.0659, found 331.0733. 
(E)-5,7-dimethoxy-3-(4-fluorobenzylidene)-4-chromanone (4g) 
Yield 63 %; mp 102-105ºC; pale yellow needles (Rf = 0.52 in 30 % ethyl acetate in hexane).  
IR: 2938 cm-1, 1646 cm-1, 1601 cm-1, 1586 cm-1, 1421 cm-1, 1290 cm-1, 1205 cm-1, 1154 cm-1, 
1078 cm-1, 1109 cm-1, 821 cm-1. HRMS calculated for C18H16FO4 (M + H+) 315.0954, found 
315.1047. 
CONCLUSION  
The synthesis and 2D-NMR elucidation of five homoisoflavanone (3-benzylidene-4-
chromanone) analogues was successfully carried out.  The synthesis of these 
homoisoflavanone analogues were based on a natural lead compound (3-benzyl-4-
chromanone) with different substitution patterns at the 4’-position of the B-ring.  We could 
confirm the influence of the R-group (R = H, OH, OMe, Cl and F) on the chemical shift of 






The NMR spectra of all products are available as supplementary material. 
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ABSTRACT 
The Hyacinthaceae family is one of the most important plant families across the eastern 
seaboard.  The (R)-enantiomer of a homoisoflavanone with anti-inflammatory activity was 
previously isolated from members of this family, namely Drimiopsis burkei Bak. and Scilla 
nervosa (Burch.) Jessop.  However the activity of the (S)-enantiomer is unknown.  In this 
paper, we report the synthesis and structural elucidation, in vivo anti-inflammatory activity 
and in vitro cytotoxic properties of both the (R)- and (S)-enantiomers and the racemate.  The 
enantiomers and racemate exhibited a relatively short duration of action and activity similar 
to that of the known non-steroidal anti-inflammatory drug diclofenac.  The naturally 
occurring enantiomer exhibited the least cytotoxicity. 
INTRODUCTION 
A homoisoflavanone, (3R)-5,7-dimethoxy-(4’-hydroxybenzyl)-4-chromanone, was 
previously isolated from Scilla nervosa (Burch.) Jessop1 as well as from Drimiopsis burkei 
Bak.2  The traditional use of S. nervosa for rheumatic fever indicates possible anti-
inflammatory properties of its constituents.3  Subsequent studies showed strong inhibition of 
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prostaglandin synthesis in microsomal cells by the isolated homoisoflavanone, supporting the 
traditional use of S. nervosa.  This compound was found to exhibit weak activity against 
COX-1 enzymes and to be inactive against COX-2 enzymes.  The anti-inflammatory activity 
can therefore not be attributed exclusively to COX enzyme inhibition, and an unknown 
mechanism of action was proposed.4 
Studies indicate that stereoselectivity plays an important role in the anti-inflammatory 
activities of non-steroidal anti-inflammatory drugs.5  The decision to employ either a 
racemate or a pure enantiomer for therapeutic purposes is usually based on the diverse 
mechanisms of actions of the enantiomers.6  The absolute configuration at C-3 of a series of 
naturally occurring homoisoflavanones was investigated using circular dichroism.7  The R-
configuration was established for all of these compounds.2, 7 Therefore, the anti-
inflammatory activity of the naturally occurring (R)-enantiomer is known, but the activity of 
the (S)-enantiomer and racemate is unknown.  A study of the anti-inflammatory activity of 
both the enantiomers could provide an answer to the question whether nature truly provides 
the best therapeutic options. 
RESULTS AND DISCUSSION 
The synthesis of the enantiomers of the homoisoflavanone from commercially available 
reagents was carried out using the general synthetic approach shown in the synthetic scheme 
(Scheme 1).  The reaction of 3,5-dimethoxyphenol 1 with 3-bromopropanoic acid using 
sodium hydride as base furnished 3-(3,5-dimethoxyphenoxy)-propanoic acid 2,8 which was 
cyclised using polyphosphoric acid to give rise to a substituted chroman-4-one 3.9  Base 
catalyzed condensation of 3 with p-hydroxybenzaldehyde resulted in 4.10  Subsequent 
reduction of the olefinic double bond of 4 in MeOH-THF (1:1) was achieved by passing 
hydrogen gas in the presence of palladium on charcoal through the solution to give rise to 5.11  
The reduction of the carbonyl group in 5, using sodium borohydrate as a reducing agent in 
MeOH, afforded a diastereomeric mixture of 6a and 6b in a ratio of 2:1 with an 88 % yield.12  
An appreciable difference in Rf values between these compounds allowed separation of the 
two diastereomers by column chromatography.  Finally, 6a and 6b were oxidized by using 




The optical rotation of both the enantiomers was measured and correlated with literature 
values of the natural homoisoflavanone to establish the absolute stereochemistry.2  It was 
found that (3R)-5,7-dimethoxy-(-4’-hydroxybenzyl)-4-chromanone correlated with 7a and 
(3S)-5,7-dimethoxy-(-4’-hydroxybenzyl)-4-chromanone with 7b.  The spectral data of 7a 
coincided with that of the natural homoisoflavanone.2 
The anti-inflammatory activities of 7a and 7b and the racemate were assessed in a mouse 
model of acute contact dermatitis.  Eight-week old male Balb/c mice of approximately 30 g 
each were used.  Equal volumes of croton oil (25 µl) were mixed with acetone (25 µl) as 
vehicle and applied (50 µl total volume; 1 hour) onto the inner surface of the right auricle of 
each mouse to induce oedema.14  The left auricle was untreated and used a negative control.  
Acetone has not been documented to have an anti-inflammatory effect by itself.15  A known 
non-steroidal anti-inflammatory drug, diclofenac, was used as a positive control.  Treatment 
of inflammation was initiated an hour after induction with croton oil and the reduction in 
oedema was measured after 3 (Fig. 1, left panel) and 6 h (Fig. 1, right panel) with 7a and 7b.  
Mice were euthanized after treatment.  From each mouse, left and right auricle biopsy 
specimens were obtained with a 6 mm biopsy punch and weighed.  Each compound at a dose 
of 0.1 mg significantly inhibited oedema after 3 and 6 h treatment (P < 0.001).  It was 
established that a dose of 0.1 mg of 7a, 7b and diclofenac exhibited optimal activity (data not 
shown).  Thus, the optimal anti-inflammatory activities of 7a, 7b and the racemate were 
comparable to that of diclofenac. 
After 3 h treatment, diclofenac inhibited oedema by 55.7 ± 8.4 %.  Compound 7a was the 
least active (50.1 ± 4.2 %), whilst compound 7b and the racemate exhibited slightly higher 
activities (58.9 ± 4.0 % and 60.0 ± 2.5 % respectively).  The difference in activity between 7a 
and the racemate was significant (P < 0.05).  After 6 h treatment, the activity of diclofenac, 
7b and the racemate decreased significantly, suggesting a relatively short duration of action.  
The difference in activity of 7a between 3 and 6 h was the least significant (P > 0.05).  After 
6 h treatment, diclofenac was the least active (34.7 ± 7.2 %; P < 0.001), followed by 7b (39.0 
± 4.6 %; P < 0.05), 7a (40.1 ± 8.4 %) and the racemate (42.4 ± 4.0 %; P < 0.01). 
Compound 7a, previously isolated from plants, was the least active at 3 h but its duration of 
action was not statistically significantly different between 3 and 6 h treatment, suggesting a 
relatively longer duration of action. 
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Cytotoxicity is an important factor to consider when testing for any biological activity.  The 
MTT assay is a colourimetric assay to determine cellular growth and survival, and compares 
well with other available assays.16, 17  The tetrazolium salt MTT was used to measure cell 
viability.  A low IC50 value indicates increased cytotoxicity, thereby decreasing the 
therapeutic potential of the compounds tested.  The in vitro cytotoxicity of the compounds 
were tested in mammalian cells and compared to diclofenac and the known cytotoxic drug 
emetine.  IC50 values are represented in Table 1.  Diclofenac was the least toxic, followed by 
7a, 7b and the racemate.  The racemate was approximately 10-fold more toxic than 7b, and 
approximately 20-fold more toxic than 7a.  This difference in cytotoxicity profiles may 
indicate interactions with different receptor systems. 
Although 7a was previously isolated from plants and tested in vitro for anti-inflammatory 
activity, no reports on the synthesis or biological activity of 7b or the racemate exist.  In vitro 
tests indicated that mechanisms other than inhibition of COX enzymes play a role in the anti-
inflammatory activity.4  The decision to employ either a racemate or a pure enantiomer 
therapeutically is usually based on the diverse mechanisms of action.6  The in vivo studies 
reported here consider all mechanisms of action and provide important insight regarding the 
activity as well as the toxicity of the enantiomers and racemate. 
Anti-inflammatory activity was found for both enantiomers and the racemate.  Compound 7b 
and the racemate were more active than 7a after 3 h treatment, however, cytotoxicity profiles 
indicated that 7a is less cytotoxic against mammalian cells.  Furthermore, 7a had a more 
sustained duration of action. 
In conclusion, 7a which is naturally found, does provide the best therapeutic option in terms 
of a favourable cytotoxicity profile.  The varying anti-inflammatory activities and 
cytotoxicity profiles seem to suggest that 7a and 7b does not share the same mechanism of 
action. 
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Figure 1.  The anti-inflammatory activity of synthetic homoisoflavanones.  Diclofenac (DF), 
7a, 7b and the racemate (Rac) at 0.1 mg each were tested in a mouse model of acute croton 
oil-induced auricular contact dermatitis.  Oedema was measured after treatment for 3 and 6 h.  
***, P < 0.001 of compound versus croton oil only control (no treatment); †, P < 0.05; ††, P 


















Scheme 1.  Reagents and conditions: (i) 3-bromopropionic acid, NaH, DMF, rt, 12h, 38 %; 
(ii) PPA, 80 °C, 4h, 45 %; (iii) para-hydroxy benzaldehyde, piperidine, 70-80 °C, 6h, 86 %; 
(iv) H2, Pd/c, MeOH-THF, rt, 0.5h, 68 %; (v) NaBH4, MeOH, rt, 1h, 88 %; (vi) CrO3, 
CH3COOH, rt, 0.5h, 40 %. 
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Table 1.  The in vitro cytotoxicity of synthetic homoisoflavanones 7a, 7b, Rac and DF 
against Chinese Hamster Ovarian (CHO-K1) cells using the MTT assay. 
Compound IC50 (µg/ml) 
DF >100 
7a 76.38 ± 7.87 
7b 36.48 ± 6.30 
Rac 3.68 ± 1.77 
emetine 0.06 ± 0.02 
EXPERIMENTAL SECTION 
General Experimental Procedures 
All reagents were obtained from Aldrich chemicals suppliers and solvents were obtained 
from a commercial supplier and used without further purification.  All reaction mixtures were 
magnetically stirred and monitored by TLC using Kieselgel 60 F254 obtained from Merck 
(Darmstadt, Germany).  1H and 13C-NMR spectra were recorded on a Bruker AVANCE III at 
400 MHz with CDCl3 as internal reference.  The value for chemical shift (δ) is given in ppm 
and coupling constants (J) in Hertz (Hz).  Melting points were recorded with a Mel-Temp 
melting point apparatus in open capillaries and are uncorrected.  Optical rotations were 
measured at room temperature in chloroform using a Perkin Elmer Polarimeter-Model 341.  
High-resolution mass spectroscopy (HRMS) data was recorded on a Waters Micromass Q-
Tof Micro mass spectrometer with a lock spray source. 
Procedure for the synthesis of 3-(3,5-dimethoxyphenoxy) propanoic acid 2 
To a mixture of 3,5 dimethoxy phenol (5.0 g, 32.46 mmol) in DMF (15 ml), NaH (0.7 g, 
32.46 mmol) was added at a temperature of 10-15 °C.  The reaction mixture was stirred at 
room temperature for 1 h.  A solution of 3-bromopropionic acid (5.9 g, 38.96 mmol) in DMF 
(15 ml) was then added dropwise at a temperature of 0 °C and the reaction mixture was 
stirred for 12 h at room temperature.   The reaction mixture was diluted with methanol (20 
ml) and acidified with 10 % HCl and extracted with ethyl acetate (3× 50 ml).  The combined 
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ethyl acetate layers were washed with water (1× 50 ml), brine (1× 50 ml) and dried over 
magnesium sulphate.  The residue obtained after evaporation of the solvent was 
chromatographed over a silica gel column, using a mixture of ethyl acetate/hexane (30:70) as 
eluent to produce the title product 2.  Yield 38 %; Rf = 0.25 (30:70 ethyl acetate/hexane); mp 
124-126 °C; light yellow powder; 1H NMR (400 MHz, CDCl3) δ: 2.83 (2H, t, J=6.2 Hz, H-
2), 3.76 (6H, s, Ar-OCH3-3’, 5’), 4.20 (2H, t, J=6.2 Hz, H-3), 6.09 (3H, s, H-2’, H-4’, H-6’); 
13C NMR (100 MHz, CDCl3) δ: 34.2 (CH2, C-1), 55.3 (OCH3, C-3’ & C-5’), 63.0 (C-2), 93.4 
(C-4’), 93.5 (C, C-2’ & C-6’), 160.2 (C-3’), 161.5 (C-5’), 176.8 (C-3); Mass m/z = 227 
(M+1)+. 
Procedure for the synthesis of 5,7-dimethoxy-4-chromanone 3 
A mixture of 3-(3,5-dimethoxyphenoxy)-propanoic acid (2.0 g, 10 mmol) and 
polyphosphoric acid (10 g) was stirred at 85-90 °C for 2 h.  The red coloured syrup thus 
obtained was poured onto crushed ice and extracted with diethyl ether (2× 50 ml).  The 
combined ether solution was washed with 3N NaOH (1× 30 ml), water (1× 50 ml) and dried 
over magnesium sulphate.  The residue obtained after evaporation of the solvent was 
chromatographed over a silica gel column using a mixture of ethyl acetate/hexane (20:80) as 
eluent to produce the title product 3.  Yield 45 %; Rf = 0.54 (20:80 ethyl acetate/hexane); mp 
101-103 °C; white powder; 1H NMR (400 MHz, CDCl3) δ: 2.71 (2H, t, J=6.4 Hz, H-3), 3.81 
(3H, s, Ar-OCH3-7), 3.87 (3H, s, Ar-OCH3-5), 4.43 (2H, t, J=6.4 Hz, H-2), 6.04 (2H, s, H-6 
& H-8); 13C NMR (100 MHz, CDCl3) δ: 38.7 (CH2, C-3), 55.5 (OCH3, C-7), 56.0 (OCH3, C-
5), 66.7 (CH2, C-2), 92.8 (CH, C-8), 93.3 (CH, C-6), 106.3 (C, C-4a), 162.2 (C, C-5), 165.2 
(C, C-8a), 165.7 (C, C-7), 189.1 (C, C-4); Mass m/z = 209 (M+1)+. 
Procedure for the synthesis of (E)-5,7-dimethoxy-3-(4-hydroxybenzylidene)-4-
chromanone 4 
A mixture of 5,7-dimethoxychroman-4-one (0.5 g, 2.4 mmol), p-hydroxybenzaldehyde (0.4 
g, 3.6 mmol) and piperidine (7-10 drops) was heated at a temperature of 80 °C for 6 h 
(reaction was monitored by TLC).  The reaction mixture was cooled, diluted with water (15 
ml) and acidified with 10 % HCl.  The mixture was then extracted with ethyl acetate (3× 30), 
and the combined ethyl acetate layer was washed with water (1× 30 ml), brine (1× 30 ml) and 
dried over magnesium sulphate.  The residue obtained after evaporation of the solvent was 
chromatographed over a silica gel column using a mixture of ethyl acetate/hexane (20:80) as 
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eluent to produce 4.  Yield 86 %; Rf = 0.41 (20:80 ethyl acetate/hexane); mp 197-200 °C; 
yellow powder; 1H NMR (400 MHz, CDCl3) δ: 3.76 (3H, s, Ar-OCH3-7), 3.82 (3H, s, Ar-
OCH3-5), 5.17 (2H, d,  J=1.4 Hz, H-2), 6.00 (1H, d, J=2.2 Hz, H-8), 6.05 (1H, d, J=2.2 Hz, 
H-6), 6.85 (2H, d, J=8.5 Hz, H-3’,5’), 7.11 (2H, d, J=8.5 Hz, H-2’,6’), 7.70 (1H, s, H-9); 13C 
NMR (100 MHz, CDCl3) δ: 54.5 (OCH3, C-7), 55.0 (OCH3, C-5), 66.5 (CH2, C-2), 92.5 (CH, 
C-6), 92.5 (CH, C-8), 106.1 (C, C-4a), 114.7 (CH, C-3’,5’), 126.0 (C, C-1’), 128.0 (C, C-3), 
130.9 (CH, C-2’,6’), 135.0 (CH, C-9), 155.9 (C, C-4’), 163.6 (C, C-8a), 164.5 (C, C-5), 164.7 
(C, C-7), 178.8 (C, C-4); HRMS (EI) calcd for C18H17O5 313.0998, found 313.1071. 
Procedure for the synthesis of 5,7-dimethoxy-3-(4-hydroxybenzyl) -4-chromanone 5 
To a solution of 5,7-dimethoxy-3-(4-hydroxybenzylidene)-4-chromanone (1.0 g, 3.2 mmol) 
in a mixture of anhydrous  MeOH/THF (1:1, 20 ml) at a temperature of 0 °C, Pd/c (0.4 g, 3.8 
mmol) was added portion wise.  H2 gas was passed through the stirred mixture at room 
temperature for 0.5 h after which it was filtered through celite and concentrated under 
reduced pressure.  The residue obtained after evaporation of the solvent was 
chromatographed over a silica gel column using mixture of ethyl acetate/hexane (20:80) as 
eluent to produce the homoisoflavanone 5.  Yield 68 %; Rf = 0.43 (20:80 ethyl 
acetate/hexane); mp 174-176 °C; light yellow powder; 1H NMR (400 MHz, CDCl3) δ: 2.65 
(1H, dd, J=10.4, 13.5 Hz, H-9a), 2.68-2.70 (1H, m, H-3), 3.15 (1H, dd, J=4.1, 13.4 Hz, H-
9b), 3.81 (3H, s, Ar-OCH3-7), 3.86 (3H, s, Ar-OCH3-5), 4.12 (1H, dd, J=4.2, 7.0 Hz, H-2a), 
4.27 (1H, dd, J=3.9, 11.2 Hz, H-2b), 6.06 (1H, s, H-8), 6.07 (1H, s, H-6), 6.80 (2H, d, J=8.4 
Hz, H-2’,6’), 7.07 (2H, d, J=8.4 Hz, H-3’,5’); 13C NMR (100 MHz, CDCl3) 32.1 (CH2, C-9), 
48.6 (CH, C-3), 55.0 (OCH3, C-7), 55.8 (OCH3, C-5), 68.8 (CH2, C-2), 92.8 (CH, C-8), 93.2 
(CH, C-6), 130.2 (CH, C-2’,6’), 105.4 (C, C-4a), 115.5 (CH, C-3’,5’), 130.4 (C, C-1’), 154.7 
(C, C-4’), 162.8 (C, C-7), 165.0 (C, C-8a), 165.7 (C, C-5), 191.9 (C, C-4); HRMS (EI) calcd 
for C18H19O5 315.1154, found 315.1224. 
Procedure for synthesis of 5,7-dimethoxy-3-(4-hydroxybenzyl) -4-chromanone 6a/6b 
NaBH4 (0.3 g, 9.5 mmol) was added portionwise to a solution of 5,7-dimethoxy-3-(4-
hydroxybenzyl)-4-chromanone (1.0 g, 3.1 mmol) in anhydrous MeOH (15 ml) at a 
temperature of 0 °C under nitrogen athmosphere.  The mixture was then allowed to reach 
room temperature and stirred for 1 h.  The reaction mixture was quenched with water and 
extracted with ethyl acetate (3×30).  The organic layer was washed with brine, dried over 
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magnesium sulphate, and concentrated under reduced pressure to produce a viscous oil 
mixture of 6a and 6b.  The residue obtained after evaporation of the solvent was 
chromatographed over a silica gel column using mixture of ethyl acetate/hexane (30:70) as 
eluent to produce an oily syrup at a yield of 88 %.  Compound 6a; Rf = 0.48 (30:70 ethyl 
acetate/hexane); oily syrup; 1H NMR (400 MHz, CDCl3) δ: 2.08-2.15 (1H, m, H-3), 2.58 
(1H, dd, J=2.6, 7.2 Hz, H-9a), 2.85 (1H, dd, J=2.6, 7.2 Hz, H-9b), 3.78 (3H, s, Ar-OCH3-5), 
3.83 (3H, s, Ar-OCH3-7), 3.99 (2H, d, J=8.2 Hz, H-2a & 2b), 4.66 (1H, d, J=2.5 Hz, H-4), 
5.99 (1H, d, J=7.1 Hz, H-8), 6.01 (1H, d, J=7.1 Hz, H-6), 6.76 (2H, d, J=8.2 Hz, H-3’,5’), 
7.12 (2H, d, J=8.0 Hz, H-2’,6’); 13C NMR (100 MHz, CDCl3) 31.9 (CH2, C-9), 40.1 (CH, C-
3), 55.3 (OCH3, C-7), 55.4 (OCH3, C-5), 59.6 (CH, C-4), 65.2 (CH2, C-2), 91.3 (CH, C-6), 
93.0 (CH, C-8), 106.6 (C, C-4a), 115.2 (CH, C-3’,5’), 130.2 (C, C-1’), 131.6 (CH, C-2’,6’), 
153.8 (C, C-4’), 155.9 (C, C-5), 159.2 (C, C-8a), 161.1 (C, C-7); Mass m/z = 317 (M+1)+.  
Compound 6b; Rf = 0.45 (30:70 ethyl acetate/hexane); oily syrup; 1H NMR (400 MHz, 
CDCl3) δ: 2.12-2.18 (1H, m, H-3), 2.40 (1H, dd, J=2.9, 7.9 Hz, H-9a), 2.55 (1H, dd, J=2.9, 
7.9 Hz, H-9b), 3.76 (3H, s, Ar-OCH3-5), 3.81 (3H, s, Ar-OCH3-7), 3.90 (1H, dd, J=1.8, 1.8 
Hz, H-2a), 4.07 (1H, dd, J=1.9, 2.0 Hz, H-2b), 4.62 (1H, s, H-4), 6.06 (1H, d, J=3.9 Hz, H-6), 
6.07 (1H, d, J=3.9 Hz, H-8), 6.74 (2H, d, J=8.3 Hz, H-3’,5’), 7.04 (2H, d, J=8.3 Hz, H-2’,6’); 
13C NMR (100 MHz, CDCl3) 33.6 (CH2, C-9), 40.5 (CH, C-3), 55.3 (OCH3, C-7), 55.5 
(OCH3, C-5), 62.9 (CH, C-4), 64.3 (CH2, C-2), 91.8 (CH, C-6), 93.2 (CH, C-8), 104.9 (C, C-
4a), 115.3 (CH, C-3’,5’), 130.2 (C, C-1’), 131.2 (CH, C-2’,6’), 154.2 (C, C-4’), 155.8 (C, C-
5), 159.8 (C, C-8a), 161.0 (C, C-7); Mass m/z = 317 (M+1)+. 
Procedure for synthesis of optically pure 5,7-dimethoxy-3-(4-hydroxybenzyl)-4-
chromanone 7a/7b 
To a mixture of either 6a or 6b respectively (0.1 g, 1.0 mmol) in acetic acid (4 ml) was added 
CrO3 (0.16 g, 5.0 mmol).  The reaction mixture was stirred at room temperature and allowed 
to stand for 0.5h.  The solvent was evaporated and extracted with ethyl acetate (2×15 ml).  
The organic layer was washed with brine (2×15 ml) and dried over magnesium sulphate.  The 
residue obtained after evaporation of the solvent was chromatographed over a silica gel 
column using a mixture of ethyl acetate/hexane (20:80) as eluent to produce the respective 
title products 7a or 7b as a semi-solid overall yield 40 %.  Compound 7a; Rf = 0.44 (20:80 
ethyl acetate/hexane); off white semi-solid; [α]25D = -25.33 (c = 0.03 g/100 mL); 1H NMR 
(400 MHz, MeOD) δ: 2.63 (1H, dd, J=10.7, 13.3 Hz, H-9a), 2.70-2.72 (1H, m, H-3), 3.15 
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(1H, dd, J=4.0, 13.5 Hz, H-9b), 3.82 (3H, s, Ar-OCH3-7), 3.87 (3H, s, Ar-OCH3-5), 4.10 (1H, 
dd, J=6.9, 11.2 Hz, H-2b), 4.27 (1H, dd, J=3.9, 11.2 Hz, H-2a), 6.06 (1H, s, H-6), 6.07 (1H, 
s, H-8), 6.80 (2H, d, J=8.4 Hz, H-2’,6’), 7.07 (2H, d, J=8.4 Hz, H-3’,5’); 13C NMR (100 
MHz, MeOD) 32.1 (CH2, C-9), 48.5 (CH, C-3), 55.0 (OCH3, C-7), 55.9 (OCH3, C-5), 68.9 
(CH2, C-2), 92.9 (CH, C-8), 93.2 (CH, C-6), 105.3 (C, C-4a), 115.5 (CH, C-3’,5’), 130.2 (C, 
C-1’), 130.3 (CH, C-2’,6’), 154.5 (C, C-4’), 162.6 (C, C-7), 165.0 (C, C-8a), 165.9 (C, C-5), 
191.7 (C, C-4); HRMS (EI) calcd for C18H19O5 315.1154, found 315.1226.  Compound 7b; Rf 
= 0.44 (20:80 ethyl acetate/hexane); off white semi-solid; [α]25D = +25.66 (c = 0.03 g/100 
mL); 1H NMR (400 MHz, MeOD) δ: 2.64 (1H, dd, J=10.4, 13.5, H-9a), 2.69-2.70 (1H, m, H-
3), 3.14 (1H, dd, J=4.1, 13.4 Hz, H-9b), 3.82 (3H, s, Ar-OMe-7), 3.86 (3H, s, Ar-OMe-5), 
4.11 (1H, dd, J=4.2, 7.0 Hz, H-2b), 4.27 (1H, dd, J=3.9, 11.2 Hz, H-2a), 6.06 (1H, s, H-6), 
6.07 (1H, s, H-8), 6.80 (2H, d, J=8.4 Hz, H-2’,6’), 7.07 (2H, d, J=8.4 Hz, H-3’,5’); 13C NMR 
(100 MHz, MeOD) 32.1 (CH2, C-9), 48.5 (CH, C-3), 55.0 (OCH3, C-7), 55.9 (OCH3, C-5), 
68.9 (CH2, C-2), 92.8 (CH, C-8), 93.2 (CH, C-6), 105.3 (C, C-4a), 115.5 (CH, C-3’,5’), 130.1 
(C, C-1’), 130.2 (CH, C-2’,6’), 154.7 (C, C-4’), 162.6 (C, C-7), 165.0 (C, C-8a), 165.9 (C, C-
5), 191.9 (C, C-4); HRMS (EI) calcd for C18H19O5 315.1154, found 315.1220. 
Assessment of croton oil-induced oedema 
Compound 7a, 7b and the racemate were assessed for their potential anti-inflammatory 
activity.  Ethical approval (003/09/Animal) from the University of KwaZulu-Natal Animal 
Ethics subcommittee was obtained prior to the investigation of acute croton oil-induced 
auricular dermatitis in a mouse model.  Guidelines by the University of KwaZulu-Natal 
Animal Ethics Subcommittee and Biomedical Resources Unit for the maintenance and 
treatment of laboratory animals were followed.  Eight-week old male Balb/c mice of 
approximately 30 g each were used.  Equal volumes of croton oil (25 µl) were mixed with 
acetone (25 µl) as vehicle and applied (50 µl total volume; 1 h) onto the inner surface of the 
right auricle of each mouse to induce oedema.14  Acetone has not been documented to have 
an anti-inflammatory effect by itself.18  Thereafter, 7a, 7b or the racemate were dissolved in 
acetone and 0.1 mg applied for 3 or 6 h treatment onto the right auricle to assess the reduction 
in oedema.  The non-steroidal anti-inflammatory drug diclofenac was included as a positive 
control.  Mice were euthanized after treatment for 3 and 6 h.  From each mouse, left and right 




In vitro cytotoxicity of 7a, 7b and the racemate was tested against a Chinese Hamster 
Ovarian (CHO-K1) cell line using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) assay.  This cell line was obtained from American Type 
Culture Collection (ATCC, CCL-61).  The MTT assay is a colourimetric assay to determine 
cellular growth and survival, and compares well with other available assays.  The tetrazolium 
salt MTT was used to measure cell viability.  The test compounds were prepared in a 2 mg/ml 
stock solution containing 10 % v/v DMSO.  Emetine was used as the reference drug at an 
initial concentration of 100 µg/ml and serially diluted in 10-fold to obtain 6 concentrations, 
the lowest being 0.001 µg/ml.  Compounds 7a, 7b and the racemate were diluted similarly.  
The DMSO solvent system had no measurable effect on cell viability (data not shown). 
Data analysis 
Data are reported as the mean ± standard error of the mean of at least three independent 
experiments with duplicate measurements.  Oedema was quantified by calculating the 
difference in weights of the right and left auricular biopsy specimens.  The value is expressed 
as a percentage of the croton oil control.  The 50 % inhibitory concentration (IC50) values of 
the cytotoxicity assays were obtained from full dose-response curves using a non-linear dose-
response curve fitting analysis.  GraphPad Prism version 5 (GraphPad Software, San Diego, 
CA, USA) was used to analyse and present the data.  Statistical comparisons were made by 
one-way ANOVA followed by Bonferroni’s post-test for multiple comparisons, or by 
Student’s two-tailed paired t test for individual comparisons to determine P values.  A value 
of P < 0.05 was considered significant. 
REFERENCES 
1. Bangani, V.; Crouch, N. R.; Mulholland, D. A. Phytochemistry 1999, 51, 947. 
2. Koorbanally, C.; Mulholland, D. A.; Crouch, N. R. Biochem. Syst. Ecol. 2006, 34, 
588. 
3. Bryant, A. Annals of the Natal Museum 1909, 21, 1. 
4. Du Toit, K.; Elgorashi, E. E.; Malan, S. F.; Drewes, S. E.; van Staden, J.; Crouch, N. 
R.; Mulholland, D. A. Bioorg. Med. Chem. 2005, 13, 2561. 
65 
 
5. Cabre, F.; Fernandez, M. F.; Calvo, L.; Ferrer, X.; Garcia, M. L.; Mauleon, D. J. Clin. 
Pharmacol. 1998, 38, 3S. 
6. Wright, M. R.; Davies, N. M.; Jamali, F. J. Pharm. Sci. 1994, 83, 911. 
7. Adinolfi, M.; Barone, G.; Corsaro, M. M.; Mangoni, L.; Lanzetta, R.; Parrilli, M. 
Tetrahedron 1988, 44, 4981. 
8. Mahapatra, T.; Jana, N.; Nanda, S. Tetrahedron: Asymmetry 2008, 19, 1224. 
9. Parham, W. E.; Huestis, L. D. J. Am. Chem. Soc. 1962, 84, 813. 
10. Siddaiah, V.; Rao, C. V.; Venkateswarlu, S.; Krishnarajub, A. V.; Subbarajub, G. V. 
Bioorg. Med. Chem. 2006, 14, 2545. 
11. Masamune, H.; Breslow, R.; Cheng, J. B.; Conklyn, M. J.; Eggler, J. F.; Marfat, A.; 
Melvin, L. S.; Pillar, J. S.; Shirley, J. T.; Showell, H. J.; Tickner, J. E. Bioorg. Med. 
Chem. Letts. 1995, 5, 887. 
12. Ferraz, H. M. C.; Bianco, G. G.; Teixeira, C. C.; Andrade, L. H.; Porto, A. L. M. 
Tetrahedron: Asym. 2007, 18, 1070. 
13. Chattopadhyay, F.; Mallik, A. K. J. Ind. Chem. Soc. 2008, 85, 1057. 
14. Della Loggia, R.; Del Negro, P.; Tubaro, A.; Barone, G.; Parrilli, M. Planta Med. 
1989, 55, 587. 
15. Lee, D.; Choo, B.; Yoon, T.; Cheon, M.; Lee, H.; Lee, A. Y.; Kim, H. J. Ethnopharm. 
2009, 121, 28. 
16. Mosmann, T. J. Immunol. Methods 1983, 65, 55. 
17. Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.; Skehan, 
P.; Scudiero, D. A.; Monks, A.; Boyd, M. R. J. Nat. Cancer Inst. 1990, 82, 1113. 
18. Lee, D. Y.; Choo, B. K.; Yoon, T.; Cheon, M. S.; Lee, H. W.; Lee, A. Y.; Kim, H. K. 







Mahidansha M. Shaikha, Glenn E.M. Maguireb, Hendrik G. Krugerb and Karen du Toita 
 
aSchool of Pharmacy and Pharmacology, University of KwaZulu-Natal, Durban, 4041, 
South Africa, and bSchool of Chemistry, University of KwaZulu-Natal, Durban, 4000, 
South Africa 
ABSTRACT  
The title compound C18H20O4, at 100 K has monoclinic (P21/c) symmetry. The structure 
displays O2—H···O1 hydrogen bonding. This hydrogen-bonding system connects the 
molecules in two dimensional plains. There is no π -stacking found in the structure. 
RELATED LITRATURE 
For examples of structural analogues see.1, 2 For synthesis see.3, 4  
 
EXPERIMENTAL 
To a solution of 5,7-dimethoxy-3-(benzyl)-4-chromanone (1.0 g, 3.3 mmol) in anhydrous 
MeOH (15 ml), NaBH4 (0.38 g, 10.0 mmol) was added portionwise at a temperature of 0 
°C under a nitrogen atmosphere. The mixture was then allowed to reach room temperature 
and stirred for 1 h. The reaction mixture was quenched with water and extracted with ethyl 
acetate (3x30 mL). The organic layer was washed with brine, dried over magnesium sulphate, 
and concentrated under reduced pressure to produce a viscous oil mixture. The residue 
obtained after evaporation of the solvent was chromatographed over a silica gel column using 
a mixture of ethyl acetate/hexane (30:70) as eluent to yield a product of 88 % (0.88 g).  
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Off-white solid; m.p. 118-121 °C. The title compound was recrystalised from a solution of 
ethyl acetate/hexane (30:70) at room temperature. 
1H NMR (400 MHz, CDCl3, δ, p.p.m.): 7.33-7.26 (m, 5H), 6.02 (d, J=2.20 Hz, 1H), 6.00 
(d, J=2.20 Hz, 1H), 4.70 (d, J=2.40 Hz, 1H), 4.02 (dd, J=3.68, 6.20 Hz, 2H), 3.77 (s, 3H), 
3.73 (s, 3H), 2.95 (dd, J=2.5, 7.4 Hz, 1H), 2.66 (dd, J=2.5, 7.4 Hz, 1H); 13C NMR 
(100 MHz, CDCl3, δ, p.p.m.): 161.1, 159.2, 155.9, 139.6, 129.1, 128.4, 126.1, 106.7, 93.0, 
91.4, 65.2, 59.6, 55.4, 55.3, 40.0, 32.9.IR: 3501, 2946, 1592, 1453, 1304, 1200, 1052; HRMS 
(EI): Calcd for C18H20O4Na 323.1254, found 323.1271. 
Crystal data 
C18H20O4     V = 1544.6 (13) Å3 
Mr = 300.34     Z = 4 
Monoclinic, P21/c    Mo Kα 
a = 9.870 (5) Å    µ = 0.09 mm−1 
b = 11.211 (6) Å    T = 100 (2) K 
c = 14.603 (7) Å    0.37 × 0.24 × 0.20 mm 
β = 107.072 (7)° 
Data collection 
Bruker Kappa Duo Apex II Diffractometer 3369 reflections with I > 2σ(I) 
Absorption correction: none   Rint = 0.021 
12055 measured reflections   Standard reflections: n/a 
3882 independent reflections 
Refinement 
R[F2 > 2σ(F2)] = 0.037   1 restraint 
wR(F2) = 0.100 H atoms treated by a mixture of independent and 
constrained refinement 
S = 1.04     Δρmax = 0.38 e Å−3 




Table 1 Hydrogen-bonding geometry (Å, °) 
D—H···A D—H H···A D···A D—H···A 
O2—
H2O···O1i 
0.952 (9) 1.931 (11) 2.8366 158.2 (15) 
Symmetry codes: (i) −x, y+1/2, −z+1/2 
COMPUTING DETIALS 
Data collection: APEX 5; cell refinement: SAINT 5; data reduction: SAINT 5; program(s) used 
to solve structure: SHELXS97 6; program(s) used to refine structure: SHELXL97 6; molecular 
graphics: OLEX27; software used to prepare material for publication: SHELXL97.8 
SUPPORTING INFORMATION 
Crystallographic information file (CIF) is avialable in CD. 
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SUMMARY AND CONCLUSION 
Four homoisoflavanones of the 3-benzylidene-4-chromanone type, of which one compound 
was novel, were synthesized and screened for anti-inflammatory activity.  None of these 
compounds were reported to exhibit anti-inflammatory activity before.   
The synthesis of two enantiomers of the 3-benzyl-4-chromanone type (one of which is 
naturally found in the plant kingdom) along with the racemate is reported. This is the first 
report of the synthesis of a homoisoflavanone enantiomer with its opposite isomer. The 
compounds were screened for anti-inflammatory activity. Optimal activity was generally 
observed after 3 hours but activity was significantly reduced after 6 hours indicating a short 
duration of action. However, the compound found in nature showed a sustained activity. The 
other enantiomer and the racemate showed potent activity comparable to that of the 
commercial drug, diclofenac but showed more pronounced cytotoxicity in comparison to the 
natural enantiomer (Chapters 2 and 5). 
Seven homoisoflavanones of the 3-benzylidene-4-chromanone type of which four were novel 
were screened for antifungal activity.  The B-ring of each compound had a different 
substitution pattern.  Antifungal activity was exhibited by all of these compounds but the 
compound containing an unsubstituted B-ring showed exceptional activity.  This suggested 
that the size and hydrophobicity of the substituent may play a important role in the activity 
(Chapter 3).  The homoisoflavanones exhibited varying degrees of cytotoxicity (Chapters 2-3 
and 5). 
The structural elucidation of all the synthesized homoisoflavanones of the 3-benzylidene-4-
chromanone and 3-benzyl-4-chromanone types is reported (Chapter-4).  
Some of the homoisoflavanones reported in this thesis exhibited significant anti-
inflammatory and antifungal activity and can be useful in the development of drugs from 
natural sources.  Some limitations were however experienced.  
1) The yields for the first two steps of the homoisoflavanone synthesis were 
comparatively low and will need to be improved.   
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2) More homoisoflavanones analogues also need to be synthesized followed by QSAR 
study to enable further modification and drug design. 
3) Only one fungal strain was used to determine the antifungal activity. A study 
including a wider variety of strains will have to be conducted.  
4) Different types of activities could be investigated for example anticancer activity.   
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HRMS spectrum of compound 7b 
